Please wait...
| ID | PMID | YEAR | Sequence | MAP | Name | C-ter MOD | N-ter MOD | Linear/Cyclic | Stereo-Chemistry | Modified | Length | Fuction | Activity | RBCs Source | Origin | Experimental structure | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10978343 | 2000 | G{nnr:W*}L{nnr:R**}{nnr:K**}AA{nnr:K**}SVG{nnr:K**}F{nnr:Y*}{nnr:Y*}{nnr:K**}H{nnr:K*}{nnr:Y*}{nnr:Y*}I{nnr:K*}AAWQIGKHAL{ct:Amid} | Styelin D | Amidation | Free | Linear | L | W* = 6-bromotryptophan, R** = dihydroxyarginine, Y* = 3,4-dihydroxyphenylalanine, K* = 5-hydroxylysine, K** = dihydroxylysine | 32 | Antimicrobial | EC50 =10 μg/ml | Human | Stylein D (blood cells of solitary ascidian Styela clava) | α-helix | NA | ||
| 10978343 | 2000 | G{nnr:W*}L{nnr:R**}{nnr:K**}AA{nnr:K**}SVG{nnr:K**}F{nnr:Y*}{nnr:Y*}{nnr:K**}H{nnr:K*}{nnr:Y*}{nnr:Y*}I{nnr:K*}AAWQIGKHAL{ct:Amid} | Styelin D | Amidation | Free | Linear | L | W* = 6-bromotryptophan, R** = dihydroxyarginine, Y* = 3,4-dihydroxyphenylalanine, K* = 5-hydroxylysine, K** = dihydroxylysine | 32 | Antimicrobial | EC50 =40 μg/ml | Sheep | Stylein D (blood cells of solitary ascidian Styela clava) | α-helix | NA | ||
| 18081258 | 2008 | GGTIFDCGETCFLGTCYTPGCSCGNYGFCYGTN{cyc:N-C} | Cycloviolacin Y1 | Free | Free | Cyclic | L | None | 33 | Anti-HIV | Poor hemolytic | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 16413829 | 2006 | GIMSLFKGVLKTAGKHVAGSLVDQLKCKITGGC | Brevinin-2TSa | Free | Free | Linear | L | None | 33 | Antimicrobial | LD50 =100μM | Human | Brevinin (skin of the Tsushima brown frog Rana tsushimensis) | NA | NA | ||
| 17451843 | 2007 | GILSSFKGVAKGVAKDLAGKLLETLKCKITGC | Ranatuerin-2CSa | Free | Free | Linear | L | None | 32 | Antimicrobial | LD50 =150μM | Human | Ranatuerin-2 analog (skin secretions of Rana cascadae) | NA | NA | ||
| 17462733 | 2007 | RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 38 | Antimicrobial | 20% hemolysis at 100 μM | Chicken | K9CATH canine cathelicidin present in neutorphil granule content | α-helix | NA | ||
| 17462733 | 2007 | RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 38 | Antimicrobial | 25% hemolysis at 100 μM | Dog | K9CATH canine cathelicidin present in neutorphil granule content | α-helix | NA | ||
| 17462733 | 2007 | RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 38 | Antimicrobial | 30% hemolysis at 100 μM | Human | K9CATH canine cathelicidin present in neutorphil granule content | α-helix | NA | ||
| 19843179 | 2009 | GMWSKIKNAGKAAKAAAKAAGKAALGAVSEAM | DRS-DA4 | Free | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolysis at 1-100μM | Rat | Dermaseptin related protein from skin of the Mexican frog, Pachymedusa dacnicolor | α-helix | Non-hemolytic | ||
| 20213310 | 2010 | RWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVKG | Papiliocin | Free | Free | Linear | L | None | 38 | Antimicrobial | 0% hemolysis at 3 - 50μM (non-hemolytic) | Human | Papiliocin (Papilio xuthus) | NA | Non-hemolytic | ||
| 20873868 | 2010 | MIRIAMKALNCFKVSGLKCWSFNSPRGQESPCPG | MIRIAM | Free | Free | Linear | L | None | 34 | Antimicrobial | 25% hemolysis at 100μg/ml | Rabbit | Sushi 1 derivative (horseshoe crab) | α Helix | NA | ||
| 20873868 | 2010 | GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS | Sushi 1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 13% hemolysis at 100μg/ml | Rabbit | Factor C protein derivative (horseshoe crab) | α Helix | NA | ||
| 20927512 | 2011 | MSVSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | Tmp1 | Free | Free | Linear | L | None | 34 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 20927512 | 2011 | MLSVSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM1 | Free | Free | Linear | L | None | 35 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 20927512 | 2011 | MVSVSVAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM2 | Free | Free | Linear | L | None | 35 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 20927512 | 2011 | MESVSVAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM3 | Free | Free | Linear | L | None | 35 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 20927512 | 2011 | MLSLSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM4 | Free | Free | Linear | L | None | 35 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 20927512 | 2011 | MESVSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1SDM1 | Free | Free | Linear | L | None | 35 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 20927512 | 2011 | MESQSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1SDM2 | Free | Free | Linear | L | None | 35 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 20927512 | 2011 | MESQSNAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1SDM3 | Free | Free | Linear | L | None | 35 | Antibacterial | 0% hemolysis at 50μM (non-hemolytic) | Sheep | Tmp1 (goat skin surface metagenome) | α Helix | Non-hemolytic | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRNLVPRTES | FALL-39 | Free | Free | Linear | L | None | 39 | Antibiotic | >25% hemolysis at 200g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRNLVPRTES | FALL-39 | Free | Free | Linear | L | None | 39 | Antibiotic | >30% hemolysis at 400g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRKLVPRTES | FALL-39-lys32 | Free | Free | Linear | L | None | 39 | Antibiotic | 30% hemolysis at 200g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRKLVPRTES | FALL-39-lys32 | Free | Free | Linear | L | None | 39 | Antibiotic | 40% hemolysis at 400g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVKRIKDFFRNLVPRTES | FALL-39-lys24 | Free | Free | Linear | L | None | 39 | Antibiotic | >30% hemolysis at 200g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVKRIKDFFRNLVPRTES | FALL-39-lys24 | Free | Free | Linear | L | None | 39 | Antibiotic | >35% hemolysis at 400g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 15325526 | 2005 | GILSSFKGVAKGVAKNLAGKLLDELKCKITGC | Ranatuerin-2AUa | Free | Free | Linear | L | None | 32 | Antimicrobial | HC50 =290µM | Human | Ranatuerin-2 from skin secretions of the Northern red-legged frog Rana aurora aurora | NA | NA | ||
| 16460023 | 2006 | FKIKPGKVLDKFGKIVGKVLKQLKKVSAVAKV | P6 | Free | Free | Linear | L | None | 32 | Hemolytic | 50% hemolysis at 90µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16621155 | 2006 | GLLDTFKNLALALNAAKSAGVLNSLSCKLSKTC | Brevinin-2GRa | Free | Free | Linear | L | None | 33 | Antimicrobial | LC50 =140µM | Human | Brevinin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GVLGTVKNLLIGAGKSAAQSVLKTLSCKLSNDC | Brevinin-2GRb | Free | Free | Linear | L | None | 33 | Antimicrobial | LC50 = 180µM | Human | Brevinin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GLFTLIKGAAKLIGKTVAKEAGKTGLELMACKITNQC | Brevinin-2GRc | Free | Free | Linear | L | None | 37 | Antimicrobial | LC50 = 100µM | Human | Brevinin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 17658606 | 2007 | DHYICAKKGGTCNFSPCPLFNRIEGTCYSGKAKCCIR | pBD-2 | Free | Free | Linear | L | None | 37 | Antimicrobial | 50% hemolysis at 128µg/ml | Porcine | Porcine defensin | NA | NA | ||
| 17658606 | 2007 | DHYICAKKGGTCNFSPCPLFNRIEGTCYSGKAKCCIR | pBD-2 | Free | Free | Linear | L | None | 37 | Antimicrobial | 10% hemolysis at 64µg/ml | Porcine | Porcine defensin | NA | NA | ||
| 17826814 | 2007 | SELAGTIIDGASLTFEVLDKVLGELGKVSRK | St I 1–31 | Free | Free | Linear | L | None | 31 | Hemolytic | Hemolytic activity expresssed as the initial rate (∆A/∆t, min- 1) i.e. at above 100 µM activity is above 0.002 min-1 | Human | Sticholysin (Stichodactyla helianthus) | NA | NA | ||
| 15304333 | 2004 | ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV | Psalmopeotoxin I (PcFK1) | Free | Free | Linear | L | None | 33 | Antimalarial | 0%hemolysis at 100µM (non-hemolytic) | Human | Venom of the tarantula Psalmopoeus cambridgei | NA | Non-hemolytic | ||
| 16460028 | 2006 | SADVAGAVIDGASLSFKILKTVLEALGNVKRK | EqTII1-32 | Free | Free | Linear | L | None | 32 | Antimicrobial | Non-hemolytic | Human | Actinoporin (Actinia equina L) | NA | Non-hemolytic | ||
| 16730859 | 2006 | VTLASHLPSDFTPAVHASLDKFLANVSTVLTSKYR | α107–141 | Free | Free | Linear | L | None | 35 | Antibacterial | Non-hemolytic | Bovine | Bovine hemoglobin | NA | Non-hemolytic | ||
| 17888907 | 2008 | GCASRCKAKCAGRRCKGWASASFRGRCYCKCFRC | Mytilin-A | Free | Free | Linear | L | None | 34 | Antimicrobial | 10% hemolysis 100 µM | Human | Synthetic peptide | NA | NA | ||
| 11242518 | 2001 | NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ{ct:Amid} | DP-107 | Amidation | Free | Linear | L | None | 38 | Hemolytic | 20-30% hemolysis at40 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 11242518 | 2001 | NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ{ct:Amid} | DP-107 | Amidation | Free | Linear | L | None | 38 | Hemolytic | 20-30% hemolysis at 40 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 15003829 | 2004 | GLMSLFKGVLKTAGKHIFKNVGGSLLDQAKCKITGEC | Brevinin-2PRa | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 55µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLMSLFRGVLKTAGKHIFKNVGGSLLDQAKCKITGEC | Brevinin-2PRb | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 65µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLMSVLKGVLKTAGKHIFKNVGGSLLDQAKCKISGQC | Brevinin-2PRc | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 125µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLMSVLKGVLKTAGKHIFKNVGGSLLDQAKCKITGQC | Brevinin-2PRd | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 100µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLLSVLKGVLKTAGKHIFKNVGGSLLDQAKCKISGEC | Brevinin-2PRe | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 80µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 11557475 | 2001 | GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS | S1 | Free | Free | Linear | L | None | 34 | Antibacterial | 0% hemolysis at 100 µg/ml (non-hemolytic) | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | Non-hemolytic | ||
| 11557475 | 2001 | GFKLKGKAKISCLPNGQWSNFPPKCIRECAMVSS | S1Δ | Free | Free | Linear | L | None | 34 | Antibacterial | 0% hemolysis at 100 µg/ml (non-hemolytic) | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | Non-hemolytic | ||
| 11557475 | 2001 | HAEHKVKIGVEQKYGQFPQGTEVTYTCSGNYFLM | S3 | Free | Free | Linear | L | None | 34 | Antibacterial | 8% hemolysis at 100 µg/ml | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | NA | ||
| 11557475 | 2001 | HAEHKVKIKVKQKYGQFPQGTEVTYTCSGNYFLM | S3Δ | Free | Free | Linear | L | None | 34 | Antibacterial | 37% hemolysis at 100 µg/ml | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | NA | ||
| 14531844 | 2003 | GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC | Ranatuerin-2BYa | Free | Free | Linear | L | None | 32 | Antibacterial | HC50 = 120µM | Human | Ranatuerin-2B analog | NA | NA | ||
| 14642822 | 2003 | GYGCPFNQYQCHSHCSGIRGYKGGYCKGTFKQTCKCY | Ornithodoros defensin A | Free | Free | Linear | L | None | 37 | Antibacterial | EC50 >100 (µg/ml) | Human | Synthetic peptide | NA | NA | ||
| 14642822 | 2003 | GYGCPFNQYQCHSHCSGIRGYKGGYCKGTFKQTCKCY | Ornithodoros defensin A | Free | Free | Linear | L | None | 37 | Antibacterial | EC50 >100 (µg/ml) | Rabbit | Synthetic peptide | NA | NA | ||
| 14637016 | 2003 | GKFSGFAKILKSIAKFFKGVGKVRKQFKEASDLDKNQ | Oxki2 | Free | Free | Linear | L | None | 37 | Antimicrobial | ~40% hemolysis at 50μM | Sheep | Oxyopinins analog (Oxyopes kitabensis) | NA | NA | ||
| 14637016 | 2003 | GKFSGFAKILKSIAKFFKGVGKVRKQFKEASDLDKNQ | Oxki2 | Free | Free | Linear | L | None | 37 | Antimicrobial | >60% hemolysis at 50μM | Pig | Oxyopinins analog (Oxyopes kitabensis) | NA | NA | ||
| 14637016 | 2003 | GKFSGFAKILKSIAKFFKGVGKVRKQFKEASDLDKNQ | Oxki2 | Free | Free | Linear | L | None | 37 | Antimicrobial | 100% hemolysis at 50μM | Guinea-pig | Oxyopinins analog (Oxyopes kitabensis) | NA | NA | ||
| 15581850 | 2004 | SIGSALKKALPVAKKIGKIALPIAKAALPVAAGLVG | CtxA | Free | Free | Linear | L | None | 36 | Antibacterial | Hemolytic at 110 µM | Human | Ceratotoxins are α-helical cationic peptides isolated from the medfly Ceratitis capitata | NA | NA | ||
| 15581850 | 2004 | SLGGVISGAKKVAKVAIPIGKAVLPVVAKLVG | CtxC | Free | Free | Linear | L | None | 32 | Antibacterial | Hemolytic 645µM | Human | Ceratotoxins are α-helical cationic peptides isolated from the medfly Ceratitis capitata | NA | NA | ||
| 15581850 | 2004 | SIGTAVKKAVPIAKKVGKVAIPIAKAVLSVVGQLVG | CtxD | Free | Free | Linear | L | None | 36 | Antibacterial | Hemolytic at 84µM | Human | Ceratotoxins are α-helical cationic peptides isolated from the medfly Ceratitis capitata | NA | NA | ||
| 12081622 | 2002 | ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE | CRAMP | Free | Free | Linear | L | None | 38 | Antibacterial | 0% hemolysis at 50 µM (non-hemolytic) | Human | CRAMP (Mouse femoral marrow cells) | NA | Non-hemolytic | ||
| 11846794 | 2002 | RLYRRLYRRLYRRLYRRLYRRLYRRLYRRLYR | (RLYR)8 | Free | Free | Linear | L | None | 32 | Antibacterial and Antifungal | EC50 = 48µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYRRLYRRLYRKKK | (RLYR)4-[K2K] | Free | Free | Linear | L | None | 35 | Antibacterial and Antifungal | EC50 = 1510µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGKKK{cyc:N-C} | (RLYRKVYG)4-[K2K] | Free | Free | Cyclic | L | None | 35 | Antibacterial and Antifungal | EC50 = 610µM | Human | Synthetic peptide | NA | NA | ||
| 10795591 | 2000 | VVCACRRALCLPLERRAGFCRIRGRIHPLCCRR | NP-2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 1.9% hemolysis at 80µg/ml | Human | Rabbit neutrophils | NA | NA | ||
| 10795591 | 2000 | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | Cecropin P1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 0.3% hemolysis at 80µg/ml | Human | Porcine intestine | NA | NA | ||
| 10795591 | 2000 | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Cecropin A | Free | Free | Linear | L | None | 37 | Antimicrobial | 0.6% hemolysis at 80µg/ml | Human | Insect hemolymph | NA | NA | ||
| 10795591 | 2000 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 17.1% hemolysis at 80µg/ml | Human | Human neutrophils | NA | NA | ||
| 10785392 | 2000 | GILDTLKQFAKGVGKDLVKGAAQGVLSTVSCKLAKTC | Gaegurin 4 (GGN4) | Free | Free | Linear | L | None | 37 | Antimicrobial | Non-hemolytic | Human | Skin of a Korean frog, Rana rugosa | NA | Non-hemolytic | ||
| 10973820 | 2000 | ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE | CRAMP | Free | Free | Linear | L | None | 38 | Antimicrobial and Anticancer | 2.2% hemolytic at 100μM | Human | Derived from CRMAP, a member of cathelicidin-derived antimicrobial peptides | NA | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear | L | None | 38 | Antimicrobial | ~2% hemolytic at 200μM | Human | Isolated from the larvae of Bombyx mori | NA | NA | ||
| 22921836 | 2012 | MAFKKLEKVGRNIRDGIIKAGPAVAVIGQATSIARPTGK | Pxcec781 | Free | Free | Linear | L | None | 39 | Antimicrobial | Non-hemolytic | Human | Cecropin 1 derivative (Plutella xylostella) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 3.13μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 6.25μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 12.5μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.1% hemolytic at 25.0μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.1 hemolytic at 50.0μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.4% hemolytic at 100mg/mL | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 3.13μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 6.25μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.3% hemolytic at 12.5μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.5% hemolytic at 25μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.6% hemolytic at 50μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.7 % hemolytic at 100mg/mL | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22670762 | 2013 | GLWDTIKQAGKKFFLNVLDKIRCKVAGGCRT | OG1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 80% hemolytic at 256 μg/mL | Porcine | Palustrin-OG1 ( Odorrana grahami) | NA | NA | ||
| 22670762 | 2013 | GLWDTIKQAGKKFFLNVLDKIRCKVAGGCRT | OG1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 10% hemolytic at 4 μg/mL | Porcine | Palustrin-OG1 ( Odorrana grahami) | NA | NA | ||
| 22249992 | 2012 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | ~9% hemolytic at 60μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22578463 | 2012 | QLKVDLWGTRSGIQPEQHSSGKSDVRRWRSRY{ct:Amid} | Ixosin-B-amide | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Ixosin-B-amide | NA | Non-hemolytic | ||
| 20858205 | 2011 | LLGDEFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | L-LL37 | Amidation | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 43.5μg/ml | Human | Synthetic peptides | NA | NA | ||
| 20858205 | 2011 | L{d}L{d}G{d}D{d}E{d}F{d}R{d}K{d}S{d}K{d}E{d}K{d}I{d}G{d}K{d}E{d}F{d}K{d}R{d}I{d}V{d}Q{d}R{d}I{d}K{d}D{d}F{d}L{d}R{d}N{d}L{d}V{d}P{d}R{d}T{d}E{d}S{d} | D-LL37 | Free | Free | Linear | D | None | 37 | Antimicrobial | HC50 = 125μg/ml | Human | Synthetic peptide | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 4.2% hemolytic at 0μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 4.1% hemolytic at 12.5μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 3.4% hemolytic at 25μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 3.0% hemolytic at 50μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 3.1% hemolytic at 100 μ g/mL | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 4.2% hemolytic at 0μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.4% hemolytic at 12.5μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.8% hemolytic at 25μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.9% hemolytic at 50μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 4.9% hemolytic at 100 μ g/mL | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22189867 | 2012 | FKCRRWQWRWKKLGAKPVPIIYCNRRTGKCQRM | LFT33 | Free | Free | Linear | L | None | 33 | Antimicrobial | Non-hemolytic upto 256 μg/ml | Human | Novel hybrid peptide of LfcinB & thanatin | NA | Non-hemolytic | ||
| 20927512 | 2011 | MSVSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | Tmp1 | Free | Free | Linear | L | None | 34 | Antimicrobial | Non-hemolytic | Sheep | Holin-like protein Tmp1derived from goat skin surface metagenome | NA | Non-hemolytic | ||
| 20927512 | 2011 | MLSVSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM1 | Free | Free | Linear | L | None | 35 | Antimicrobial | Non-hemolytic | Sheep | Mutants of holin-like protein Tmp1 | NA | Non-hemolytic | ||
| 20927512 | 2011 | MVSVSVAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM2 | Free | Free | Linear | L | None | 35 | Antimicrobial | Non-hemolytic | Sheep | Mutants of holin-like protein Tmp1 | NA | Non-hemolytic | ||
| 20927512 | 2011 | MESVSVAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM3 | Free | Free | Linear | L | None | 35 | Antimicrobial | Non-hemolytic | Sheep | Mutants of holin-like protein Tmp1 | NA | Non-hemolytic | ||
| 20927512 | 2011 | MLSLSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1RM4 | Free | Free | Linear | L | None | 35 | Antimicrobial | Non-hemolytic | Sheep | Mutants of holin-like protein Tmp1 | NA | Non-hemolytic | ||
| 20927512 | 2011 | MESVSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1SDM1 | Free | Free | Linear | L | None | 35 | Antimicrobial | Non-hemolytic | Sheep | Mutants of holin-like protein Tmp1 | NA | Non-hemolytic | ||
| 20927512 | 2011 | MESQSDAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1SDM2 | Free | Free | Linear | L | None | 35 | Antimicrobial | Non-hemolytic | Sheep | Mutants of holin-like protein Tmp1 | NA | Non-hemolytic | ||
| 20927512 | 2011 | MESQSNAVQLMLGFGTFVLMLLGLVVELIKNSNKK | T1SDM3 | Free | Free | Linear | L | None | 35 | Antimicrobial | Non-hemolytic | Sheep | Mutants of holin-like protein Tmp1 | NA | Non-hemolytic | ||
| 20399752 | 2010 | KRFKKFFKKLKNSVKKRAKKFFKKPKVIGVTFPF | NA-CATH | Free | Free | Linear | L | None | 34 | Antimicrobial | EC50 =0.37μM | Human | Naja atra (cathelicidin) | α-helical | NA | ||
| 20399752 | 2010 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | EC50 =0.05μM | Human | cathelicidin | α-helical | NA | ||
| 20493915 | 2010 | RWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | ABP-CM4 | Free | Free | Linear | L | None | 35 | Antimicrobial and Cytotoxic | 0% hemolysis at 200μM | Human | Bombyx mori | α-helical | NA | ||
| 20493915 | 2010 | RWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | ABP-CM4 | Free | Free | Linear | L | None | 35 | Antimicrobial and Cytotoxic | 5% hemolysis at 400μM | Human | Bombyx mori | α-helical | NA | ||
| 20735987 | 2010 | CIAKGNGCQPSGVQGNCCSGHCHKEPGWVAGYCK{ct:Amid} | Psacotheasin | Amidation | Free | Linear | L | None | 34 | Antifungal | 0% hemolysis at 100μM | Human | Psacothea hilaris | NA | Non-hemolytic | ||
| 22943778 | 2012 | GIMRVFKGVLKTAGKSVAKNVAGSFLDRLKCKISGGC{cyc:N-C} | Brevinin-2ZHa | Free | Free | Cyclic | L | None | 37 | Antimicrobial | HC50 =52μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22973850 | 2013 | DHYICAKKGGTCNFSPCPLFNRIEGTCYSGKAKCCIR | pBD2 | Free | Free | Linear | L | None | 37 | Antimicrobial | 12% hemolysis at 80μg/ml | Porcine | Synthetic peptide | α-helical | NA | ||
| 23328867 | 2013 | THRPPMWSPVWPGGGKLL{d}LKL{d}LK{d}K{d}LLKL{d}LKKK | TfR-lytic hybrid peptide | Free | Free | Linear | Mix | None | 32 | Anticancer | 17% hemolysis at 100μM | Mouse | Synthetic peptide | NA | NA | ||
| 23523532 | 2013 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cu 1a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 =7.8μM | Human | Derived from venom of Cupiennius salei | α-helical | NA | ||
| 23523532 | 2013 | GAGALAKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | A-Cu 1a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 >40μM | Human | Cu 1a analog | α-helical | NA | ||
| 23523532 | 2013 | GKGALKKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | K-Cu 1a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 >40μM | Human | Cu 1a analog | α-helical | NA | ||
| 23523532 | 2013 | GFGTILKALAKIAGKVVKKLATKPGATYMLKENLK{ct:Amid} | Cu 2a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 =2.6μM | Human | Derived from venom of Cupiennius salei | α-helical | NA | ||
| 8163497 | 1994 | GLMDTLKNLAKTAGKGALQSLLNKASCKLSGQC | Brevinin-2E | Free | Free | Linear | L | None | 33 | Antimicrobial | Lethal concentration >100μM | Human | Derived from skin secretion of Rana esculenta(Brevinin analog) | NA | NA | ||
| 11792701 | 2002 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cupiennin-1a | Amidation | Free | Linear | L | None | 35 | Antimicrobial | EC50 = 24.4μM | Human | Cupiennin analog (Venom of the Spider Cupiennius salei (Ctenidae)) | NA | NA | ||
| 11792701 | 2002 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME | Cupiennin-1a | Free | Free | Linear | L | None | 35 | Antimicrobial | EC50 = 20.5μM | Human | Cupiennin analog (Venom of the Spider Cupiennius salei (Ctenidae)) | NA | NA | ||
| 11792701 | 2002 | GFGSLFKFLAKKVAKTVAKQAAKQGAKYVANKHME | Cupiennin-1d | Free | Free | Linear | L | None | 35 | Antimicrobial | EC50 = 14.5μM | Human | Cupiennin analog (Venom of the Spider Cupiennius salei (Ctenidae)) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKGIGKFLHSAKKFGKAFVGEIMNS | Peptide-3 | Free | Free | Linear | L | None | 33 | Antibacterial | 0% hemolysis upto 200μg/ml (non hemolytic) | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | Non-hemolytic | ||
| 1605597 | 1992 | AAAAAAAAAAGIGKFLHSAKKFGKAFVGEIMNS | Peptide-4 | Free | Free | Linear | L | None | 33 | Antibacterial | 2% hemolysis upto 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | AAAAAAAAAAGIGKFLHSAKKFGKAFVGEIMNS | Peptide-4 | Free | Free | Linear | L | None | 33 | Antibacterial | 9% hemolysis upto 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 0% hemolysis at 25μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 1% hemolysis at 50μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 2% hemolysis at 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 4% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | GIGKFLHSAKKFGKAFVGEIMNSKKKKKKKKKK | Peptide-7 | Free | Free | Linear | L | None | 33 | Antibacterial | 0% hemolysis upto 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | GIGKFLHSAKKFGKAFVGEIMNSKKKKKKKKKK | Peptide-7 | Free | Free | Linear | L | None | 33 | Antibacterial | 1% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKGIGKLFLHAAKKFAKAFVAEKMNS | Peptide-10 | Free | Free | Linear | L | None | 34 | Antibacterial | 0% hemolysis at 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKGIGKLFLHAAKKFAKAFVAEKMNS | Peptide-10 | Free | Free | Linear | L | None | 34 | Antibacterial | 2% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 12067731 | 2002 | WLNALLHHGLNCAKGVLAWLNALLHHGLNCAKGVLA | 18 homodimer halocidin | Free | Free | Linear | L | None | 36 | Antimicrobial | ~1-2% hemolysis at 25μg/ml | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 12067731 | 2002 | WLNALLHHGLNCAKGVLAWLNALLHHGLNCAKGVLA | 18 homodimer halocidin | Free | Free | Linear | L | None | 36 | Antimicrobial | >10% hemolysis at 100μg/ml | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 2689223 | 1989 | KWKLFKKIEKVGQNIRDGIIKAGPGIGAVLKVLTTGL{ct:Amid} | CA(1-24)M(1-13) | Amidation | Free | Linear | L | None | 37 | Antibacterial and Antiparasitic | Lethal concentration calculated from zone of inhibition >200μM | Sheep | Cercropin-melittin hybrids | NA | NA | ||
| 9395500 | 1997 | {nnr:X}ALWKNMLKGIGKLAGKAALGAVKKLVGAES | DS3 | Free | Free | Linear | L | X = H | 31 | Antimicrobial and Cytolytic | No hemolysis at 34μM (non hemolytic) | Human | Dermaseptins (skin of the tree frogs) | NA | Non-hemolytic | ||
| 15304333 | 2004 | ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV{ct:Amid} | PcFK1 | Amidation | Free | Linear | L | None | 33 | Antiplasmodial | No hemolysis at 10μM (non hemolytic) | Human | Psalmopeotoxins (venom of the Trinidad chevron tarantula Psalmopoeus cambridgei) | NA | Non-hemolytic | ||
| 22074926 | 2012 | CGESCVFIPCITSLAGCSCKNKVCYYDGGSVP{cyc:N-C} | Parigidin_br1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 41% hemolysis at 40µM | Human | Parigidinbr1 (Palicourea rigida) | NA | NA | ||
| 22074926 | 2012 | CGESCVFIPCITSLAGCSCKNKVCYYDGGSVP{cyc:N-C} | Parigidin_br1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 28% hemolysis at 20µM | Human | Parigidinbr1 (Palicourea rigida) | NA | NA | ||
| 19085906 | 2008 | GFWKKVGSAAWGGVKAAAKGAAVGGLNALAKHIQ | Papillosin | Free | Free | Linear | L | None | 34 | Antimicrobial | 0% hemolysis upto 50µM (Non hemolytic) | Sheep | Papillosin (Halocynthia papillosa) | NA | Non-hemolytic | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGG | Pardaxin | Free | Free | Linear | L | None | 31 | Antibacterial | >20% hemolysis at 25µM | Human | Pardaxin (Pardachirus marmoratus) | NA | NA | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGG | Pardaxin | Free | Free | Linear | L | None | 31 | Antibacterial | >50% hemolysis at 50µM | Human | Pardaxin (Pardachirus marmoratus) | NA | NA | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE{ct:[NH(CH2)2NH2]2} | Pardaxin- [NH(CH2)2NH2]2 | [NH(CH2)2NH2]2 | Free | Linear | L | None | 33 | Antibacterial | >100% hemolysis at 12µM | Human | Pardaxin analog (Pardachirus marmoratus) | NA | NA | ||
| 7989335 | 1994 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | DS s1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 100% hemolysis at >70µM | Human | Dermaseptin analog (Phyllomedusa sauvagii) | NA | NA | ||
| 7989335 | 1994 | ALWKTMLKKLGTMALHAGKAALGAAANTISQGTQ | DS s2 | Free | Free | Linear | L | None | 34 | Antimicrobial | 100% hemolysis at 70µM | Human | Dermaseptin analog (Phyllomedusa sauvagii) | NA | NA | ||
| 7999137 | 1994 | SLFSLIKAGAKFLGKNLLKQGACYAACKASKQC | Gaegurin 1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0.59% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | GIMSIVKDVAKNAAKEAAKGALSTLSCKLAKTC | Gaegurin 2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0.82% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | GIMSIVKDVAKTAAKEAAKGALSTLSCKLAKTC | Gaegurin 3 | Free | Free | Linear | L | None | 33 | Antimicrobial | 1.20% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | GILDTLKQFAKGVGKDLVKGAAQGVLSTVSCKLALTC | Gaegurin 4 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1.67% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 18295522 | 2007 | QLKVDLWGTRSGIQPEQHSSGKSDVRRWRSRY | Ixosin-B | Free | Free | Linear | L | None | 32 | Antimicrobial | Little hemolysis upto 200µg/ml | Rabbit | Derived from the salivary glands of Ixodes sinensis | NA | NA | ||
| 9010936 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE | PX | Free | Free | Linear | L | None | 33 | Antimicrobial | 100% hemolysis at 14μg/ml | Human | Derived from the amino terminal region of the toxin pardaxin | NA | NA | ||
| 9108731 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE | PX1–33 | Free | Free | Linear | L | None | 33 | Cytolytic | Conc. Required for hemolysis =1.75nmols | Human | Synthetic Peptide | NA | NA | ||
| 9108731 | 1996 | GFFALIAKIISSPLFKTLLSAVGSALSSSGEQE | PX1–33 (P7A) | Free | Free | Linear | L | None | 33 | Cytolytic | Conc. Required for hemolysis =0.6nmols | Human | Synthetic Peptide | NA | NA | ||
| 9395500 | 1997 | HALWKNMLKGIGKLAGKAALGAVKKLVGAES | DS3 | Free | Free | Linear | L | None | 31 | Cytotoxic | 50% hemolysis at 50μM | Human | Dermaseptin | NA | NA | ||
| 9639668 | 1998 | IIKVPLKKFKSMREVMRDHGIKAPVVDPATKY | bPcAP | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.36% hemolysis at 200μg/ml | Human | Isolated from the stomach of the bullfrog, Rana catesbeiana | NA | NA | ||
| 18568863 | 2008 | RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 38 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | MHC ~100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 8306981 | 1994 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | Dermaseptin I | Free | Free | Linear | L | None | 34 | Antimicrobial | 100% hemolysis at 100μM | Rabbit | Phyllomedusa sauvugii | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAAVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O6 | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAVVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O11 | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVFIPCISTLLGCSCKNKVCYRNGVIP{cyc:N-C} | Circulin B | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 17561225 | 2007 | GLWSKIKEAAKAAGKAALNAVTGLVNQGDQPS | Dermaseptin-L1 | Free | Free | Linear | L | None | 32 | Antimicrobial | LC50 =200μM | Human | Skin secretions of the lemur leaf frog Hylomantis lemur | NA | NA | ||
| 19778602 | 2010 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT | Nigroain-K2 | Free | Free | Linear | L | None | 31 | Antimicrobial | 85.52±3.26% hemolysis at 100μg/ml | Rabbit | Skin secretions of Rana nigrovittata | NA | NA | ||
| 19778602 | 2010 | SIRDKIKTIAIDLAKSAGTGVLKTLICKLDKSC | Rugosin-RN1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 6.69±1.51% hemolysis at 100μg/ml | Rabbit | Skin secretions of Rana nigrovittata | NA | NA | ||
| 14531844 | 2003 | GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC | Ranatuerin-2BYa | Free | Free | Linear | L | None | 32 | Antimicrobial | HC50 = 120μM | Human | Rana boylii | NA | NA | ||
| 16460023 | 2006 | FKIKASKVLDKFGKIVGKVLKQLKKVSAVAKV | P6_1 | Free | Free | Linear | L | None | 32 | Hemolytic | LD50=12.6µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | FSISASKVLDKFGKIVGKVLKQLKKVSAVAKV | P6_2 | Free | Free | Linear | L | None | 32 | Hemolytic | LD50=28.1µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | Bombyx Mori | α-Helix | Non-hemolytic | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bombyx Mori | α-Helix | Non-hemolytic | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | <5 % Hemolysis at 100 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | <5 % Hemolysis at 200 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | 10 % Hemolysis at 400 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | 30 % Hemolysis at 800 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23689723 | 2013 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | No Hemolysis at 100 µM | Human | Human Cathelicidin | NA | Non-hemolytic | ||
| 23632907 | 2013 | GLFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC | Brevinin-2RNa | Free | Free | Linear | L | None | 33 | Antimicrobial | 50 % Hemolysis at 65.2 ± 7.6 µM | Human | Black-Spotted Frog,Rana Nigromaculata | α-Helix | NA | ||
| 23737519 | 2013 | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | cecropin B (CB) | Free | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Cecropia Moth Hyalophora Cecropia | α-Helix | NA | ||
| 23737519 | 2013 | KWKVLKKKIKMLRNRINGLVKAGPALKVKLQALAL | cecropin B template (cBt) | Free | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Cecropia Moth Hyalophora Cecropia | α-Helix | NA | ||
| 23737519 | 2013 | EAQNLEKEIAALEQAIQGLEKEIPALAQQIQALEL | anti-cecropin B template (anti-cBt) | Free | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Cecropia Moth Hyalophora Cecropia | α-Helix | NA | ||
| 23933745 | 2013 | (C(RQIKIWFQNRRMKWKKRQIKIWFQNRRMKWKK){nnr:x}GG)KK{d}K{nnr:*}{nt:Acet}{ct:Amid} | Antp-G1a | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 39 | Antimicrobial | 1 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 24105706 | 2013 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 175 µM | Human | Human Leukocytes And Epithelia | α-Helix | NA | ||
| 23523532 | 2013 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cu 1a | Amidation | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at 7.8 (7.5–8.2) µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 23523532 | 2013 | G{nnr:a}GAL{nnr:a}KFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cu 2a | Amidation | Free | Linear | L | a = exchanged residues of A-Cu 1a and K-Cu 1a | 35 | Antimicrobial | 50 % Hemolysis at 2.6 (2.4–2.8) µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 23523532 | 2013 | G{nnr:k}GAL{nnr:k}KFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | A-Cu 1a | Amidation | Free | Linear | L | k = exchanged residues of A-Cu 1a and K-Cu 1a | 35 | Antimicrobial | 50 % Hemolysis at >40 µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 23523532 | 2013 | GFGTILKALAKIAGKVVKKLATKPGATYMLKENLK{ct:Amid} | K-Cu 1a | Amidation | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >40 µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 24055160 | 2013 | GLRDKIKNVAIDVAKGAGTGVLKALLCOLDKSC | Brevinin-2SN1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 31.8 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GVLDTLKNVAIGVAKGAGTGVLKALLCQLDKSC | Brevinin-2SN2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 50.1 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GIFSLFKAGAKFFGKNLLKEAGKAGAEHLACKAANQC | Esculentin-2SN1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | GLRDKIKNVAIDVAKGAGTGVLKALLCOLDKSC | Brevinin-2SN1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 54.1 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GVLDTLKNVAIGVAKGAGTGVLKALLCQLDKSC | Brevinin-2SN2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 91.4 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GIFSLFKAGAKFFGKNLLKEAGKAGAEHLACKAANQC | Esculentin-2SN1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | GLRDKIKNVAIDVAKGAGTGVLKALLCOLDKSC | Brevinin-2SN1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 90.2 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GVLDTLKNVAIGVAKGAGTGVLKALLCQLDKSC | Brevinin-2SN2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 100 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GIFSLFKAGAKFFGKNLLKEAGKAGAEHLACKAANQC | Esculentin-2SN1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 9.1 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP194 | Free | Free | Linear | L | None | 31 | Antimicrobial | 71 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP196 | Free | Free | Linear | L | None | 31 | Antimicrobial | 61 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKKLFKKILKYL | BP204 | Free | Free | Linear | L | None | 33 | Antimicrobial | 97 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP215 | Free | Free | Linear | L | None | 31 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP194 | Free | Free | Linear | L | None | 31 | Antimicrobial | 87 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP196 | Free | Free | Linear | L | None | 31 | Antimicrobial | 66 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKKLFKKILKYL | BP204 | Free | Free | Linear | L | None | 33 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP215 | Free | Free | Linear | L | None | 31 | Antimicrobial | 3 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP194 | Free | Free | Linear | L | None | 31 | Antimicrobial | 932 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP196 | Free | Free | Linear | L | None | 31 | Antimicrobial | 74 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKKLFKKILKYL | BP204 | Free | Free | Linear | L | None | 33 | Antimicrobial | 100 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP215 | Free | Free | Linear | L | None | 31 | Antimicrobial | 14 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24102775 | 2014 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP100.C | Free | Free | Linear | L | None | 31 | Antimicrobial | 0.1 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | Non-hemolytic | ||
| 24652097 | 2014 | KKKHRQFLGIRNYYKEFIPNLSDITSPLHVLLKK | SmAE_P1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Mouse | Synthetic | α-Helix | Non-hemolytic | ||
| 24652097 | 2014 | YFCTCNVKGFNAKNKRGIIYPNLPSAMRPVAHGPGIPVP | SmAE_P15 | Free | Free | Linear | L | None | 39 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Mouse | Synthetic | α-Helix | Non-hemolytic | ||
| 24652097 | 2014 | PSGHQREDLINRHLRFECPFQSLIVCHHHHHHHHHHHH | SmAE_P17 | Free | Free | Linear | L | None | 38 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Mouse | Synthetic | α-Helix | Non-hemolytic | ||
| 24652097 | 2014 | ANLATHRRLHKGESSDHCNYCGTSFTRKSHLLRHQRI | SmAE_P18 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Mouse | Synthetic | α-Helix | Non-hemolytic | ||
| 24666608 | 2014 | NNSKAKCGDLAGWSKLTFKSADECTKTGQKS | oshem 2 | Free | Free | Linear | L | None | 31 | cytotoxic | 32.9 ± 8.7 % Hemolysis at 0.2 mg/L | Human | Jellyfish Olindias Sambaquiensis | Random coils | NA | ||
| 24168384 | 2014 | GFFLNALKNFAKTAGKRLKSLLNHASCKLSGQC | Cyanophlyctin b | Free | Free | Linear | L | None | 33 | Antibacterial | 0.7 % Hemolysis at 500 µg/ml | Human | Skin Secretions Of Euphlyctis Cyanophlyctis | α-Helix | Non-hemolytic | ||
| 24871991 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | L(LL37) | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 32 μg/ml | Sheep | Human Leukocytes And Epithelia | α-Helix | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 0 % Hemolysis at 0.75 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | Non-hemolytic | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 0.84 % Hemolysis at 1.5 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 1.01 % Hemolysis at 3 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 1.18 % Hemolysis at 6 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 1.37 % Hemolysis at 12 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 2.61 % Hemolysis at 48 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 1 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | <10 % Hemolysis at 10 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | <20 % Hemolysis at 100 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | <40 % Hemolysis at 200 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 25016054 | 2014 | ENFFKEIERAGQRIRDAIISAAPAVETLAQAQKIIKGGD | GM1 | Free | Free | Linear | L | None | 39 | Antibacterial, Anti-infective | 0 % Hemolysis at 100 μg/ml | Human | Galleria Mellonella Native | NA | Non-hemolytic | ||
| 25016054 | 2014 | ENFFKEKERKGQRIRDAIISRRPRVETLAQAQKIIKGGD | ΔGm1 | Free | Free | Linear | L | None | 39 | Antibacterial, Anti-infective | 0 % Hemolysis at 100 μg/ml | Human | Galleria Mellonella Native Analogue | NA | Non-hemolytic | ||
| 25100358 | 2014 | KRFKKFFKKLKNSVKKRAKKFFKKPRVIGVSIPF | Oh_CRAMP | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at 100 µM | Human | Reptilian Cramps From Elapids | α-Helix | NA | ||
| 25100358 | 2014 | KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF | crotalicidin | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at 25 µM | Human | Reptilian Cramps From Pit Vipers | α-Helix | NA | ||
| 25100358 | 2014 | KRFKKFFKKLKNSVKKRVKKFFRKPRVIGVTFPF | batroxicidin | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at 12.5 µM | Human | Reptilian Cramps From Pit Vipers | α-Helix | NA | ||
| 25100358 | 2014 | KRFKKFFMKLKKSVKKRVMKFFKKPMVIGVTFPF | Pt_ CRAMP1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at ~6.25 µM | Human | Reptilian Cramps From Elapids | α-Helix | NA | ||
| 25100358 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | Pt_ CRAMP1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 50 µM | Human | Reptilian Cramps From Elapids | α-Helix | NA | ||
| 24466055 | 2014 | GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG{ct:Amid} | PMAP-36 | Amidation | Free | Linear | L | None | 36 | Antimicrobial | <40 % Hemolysis at 128 µM | Human | Porcine Myeloid Antimicrobial Peptide-36 | α-Helix | NA | ||
| 25257597 | 2015 | AYVLDEPKPIKDLEKSLQHNLVYCRRLVLEYFLKSIFEYH | SRTAP-40 | Free | Free | Linear | L | None | 40 | Antimicrobial | 1.5 % Hemolysis at 192 μg/ml | Rabbit | Sheep Reproductive Tract | NA | NA | ||
| 26156126 | 2015 | RWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RAKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin-2A | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RWKIAKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin-5A | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RAKIAKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin-2A5A | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26194630 | 2015 | LIQRGRFGRFLGRIRRFRPRINFDIRARGSIRLG | Cl-CATH2 | Free | Free | Linear | L | None | 34 | Antimicrobial | 12.84 % Hemolysis at 200 μg/ml | Human | Columba Livia | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKGAGKQLIAHAMEKIAEKVGLNKDGN | ocellatin-PT6 | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.69 ± 0.04 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKGAGKQLIAHAMGKIAEKVGLNKDGN | ocellatin-PT7 | Free | Free | Linear | L | None | 32 | Antimicrobial | 13.72 ± 1.29 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKGAGKQLIARAMGKIAEKVGLNKDGN | ocellatin-PT8 | Free | Free | Linear | L | None | 32 | Antimicrobial | 8.09 ± 0.52 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 25620367 | 2015 | GFGCNGPWNEDDLRCHNHCKSIKGYKGGYCAKGGFVCKCY | NZ2114 | Free | Free | Linear | L | None | 40 | Antibacterial | <0.05 % Hemolysis at 128 μg/ml | Human | Variant Of Nz2114 | α-Helix | Low hemolytic | ||
| 25620367 | 2015 | GFGCNGPWQEDDVKCHNHCKSIKGYKGGYCAKGGFVCKCY | MP1102 | Free | Free | Linear | L | None | 40 | Antibacterial | <0.05 % Hemolysis at 128 μg/ml | Human | Pseudoplectania Nigrella | α-Helix | Low hemolytic | ||
| 26134716 | 2015 | SELAGTIIDGASLTFEVLDKVLGELGKVSRK{ct:Amid} | StI1-31 | Amidation | Free | Linear | L | None | 31 | Hemolytic | 50 % Hemolysis at 7.25 ± 0.01 nM | Human | Stichodactyla Helianthus | α-Helix | NA | ||
| 26134716 | 2015 | SADVAGAVIDGASLSFDILKTVLEALGNVKRK{ct:Amid} | EqtII1-32 | Amidation | Free | Linear | L | None | 32 | Hemolytic | 50 % Hemolysis at 0.91 ± 0.01 nM | Human | Actinia Equina | α-Helix | NA | ||
| 26134716 | 2015 | SADVAGAVIDGAGLGFDVLKTVLEALGNVKRK{ct:Amid} | FraC1-32 | Amidation | Free | Linear | L | None | 32 | Hemolytic | 50 % Hemolysis at 0.96 ± 0.06 nM | Human | Actinia Fragacea | α-Helix | NA | ||
| 26091834 | 2015 | SSRRPCRGRSCGPRLRGGYTLIGRPVKNQNRPKYMWV | BG-CATH37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 400 μg/ml | Human | Toad Bufo Bufo Gargarizans | Random-coil | NA | ||
| 26091834 | 2015 | PCRGRSCGPRLRGGYTLIGRPVKNQNRPKYMWV | BG-CATH(5- 37) | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 400 μg/ml | Human | Toad Bufo Bufo Gargarizans | Random-coil | NA | ||
| 26656394 | 2015 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY | Cap18 | Free | Free | Linear | L | None | 37 | Antibacterial | 1 ± 0 % Hemolysis at 64 μg/ml | Horse | Mammalian, Rabbit, Neutrophils | α-Helical | NA | ||
| 26656394 | 2015 | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | Cecropin P1 | Free | Free | Linear | L | None | 31 | Antibacterial | 0 ± 0 % Hemolysis at 256 μg/ml | Horse | Mammalian, Pig, Small Intestine | α-Helical | Non-hemolytic | ||
| 26656394 | 2015 | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG{ct:Amid} | Cecropin B | Amidation | Free | Linear | L | None | 36 | Antibacterial | 0 ± 0 % Hemolysis at 256 μg/ml | Horse | Insects, Giant Silk Moth, Pupae | α-Helical | Non-hemolytic | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.25 % Hemolysis at 1 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.25 % Hemolysis at 5 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.25 % Hemolysis at 10 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.3 % Hemolysis at 25 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.35 % Hemolysis at 50 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.45 % Hemolysis at 100 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26656137 | 2016 | LVQRGRFGRFLKKVRRFIPKVIIAAQIGSRFG | Cc-CATH2 | Free | Free | Linear | L | None | 32 | Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Coturnix Coturnix | α-Helix | NA | ||
| 26656137 | 2016 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antifungal | 50 % Hemolysis at 75 μg/ml | Human | Homo Sapiens | α-Helix | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 0.78 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | 3 % Hemolysis at 1.56 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 3.13 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 6.25 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 12.5 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 25 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 5 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 100 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | 3 % Hemolysis at 200 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 27014065 | 2016 | GSKKPVPIIYCNRRSGKCQRMGSIRTPKISKPIKFELSG | PTS | Free | Free | Linear | L | None | 39 | Antimicrobial | <15 % Hemolysis at 1 mmol/L | Human | Hybrid Peptide | Random coil | NA | ||
| 27187467 | 2016 | GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI{ct:Amid} | Dermaseptin-PD-2 | Amidation | Free | Linear | L | None | 32 | Antibacterial, Antifungal, Anticancer | 100 % Hemolysis at >161.6 µM | Horse | Pachymedusa Dacnicolor | α-Helix | Low hemolytic | ||
| 27251456 | 2016 | GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG{ct:Amid} | PMAP-36 | Amidation | Free | Linear | L | None | 36 | Antibacterial, Antifungal | 5 % Hemolysis at 4 µM | Human | Cathelicidin-Related | α-Helix(50% TFE and 30 mM SDS) | NA | ||
| 27367675 | 2016 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | L | Free | Free | Linear | L | None | 37 | Antibacterial | 50 % Hemolysis at 32 ± 0.68 µg/mL | Sheep | Human Leukocytes And Epithelia | α-Helix | NA | ||
| 27367675 | 2016 | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | C-L | Free | Free | Linear | L | None | 37 | Antibacterial | 50 % Hemolysis at 169 ± 15.1 µg/mL | Sheep | Hyalophora Cecropia | α-Helix | NA | ||
| 27542832 | 2016 | PPPVIKFNRPFLMWIVERDTRSILFMGKIVNPKAP | A1P | Free | Free | Linear | L | None | 35 | Antimicrobial | <1 % Hemolysis at 300 µg/mL | Sheep | American Alligator, Alligator Mississippiensis | α-Helix | Non-hemolytic | ||
| 27542832 | 2016 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | <1 % Hemolysis at 300 µg/mL | Sheep | Human Camp | Random or Disordered | Non-hemolytic | ||
| 27698732 | 2016 | LVQRGRFGRFLRKIRRFRPKVTITIQGSARF | fowlicidin-2 | Free | Free | Linear | L | None | 31 | Antimicrobial | 50 % Hemolysis at 128-256 μg/ml | Human | Pichia Pastoris X-33 | α-Helical | NA | ||
| 27487329 | 2017 | GGVCGETCRRDSDCPGACICRGNGYCGSGSD{cyc:N-C} | ML1 | Free | Free | Cyclic | L | None | 31 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCVGGTCPGACICRGNGYCGSGSD{cyc:N-C} | ML2 | Free | Free | Cyclic | L | None | 33 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCNTPGCICRGNGYCGSGSD{cyc:N-C} | ML3 | Free | Free | Cyclic | L | None | 35 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCPGACTCRGNGYCGSGSD{cyc:N-C} | ML4 | Free | Free | Cyclic | L | None | 34 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCPGACICRGNGYCGSGSD{cyc:N-C} | MCoTI-II | Free | Free | Cyclic | L | None | 34 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Momordica Cochinchinensis | Loop | Non-hemolytic | ||
| 28008655 | 2017 | KWKFFKKIERVGQNIRDGIIKAGPAVAVVGQATNIAKG{ct:Amid} | M-ApCec | Amidation | Free | Linear | L | None | 38 | cytotoxic | 0 % Hemolysis at 1.95-62.5 µM | Mouse | Antheraea Pernyi | α-Helix | NA | ||
| 28008655 | 2017 | KWKFFKKIERVGQNIRDGIIKAGPAVAVVGQATNIAKG{ct:Amid} | M-ApCec | Amidation | Free | Linear | L | None | 38 | cytotoxic | ~10 % Hemolysis at 121.55 µM | Mouse | Antheraea Pernyi | α-Helix | NA | ||
| 27876749 | 2017 | KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF{ct:Amid} | Ctn | Amidation | Free | Linear | L | None | 34 | Antifungal | 70 % Hemolysis at 12.5 µM | Human | South American Rattlesnake Crotalus Durissus Terrificus | α-Helix | NA | ||
| 27876749 | 2017 | KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF{ct:Amid} | Ctn | Amidation | Free | Linear | L | None | 34 | Antifungal | 80 % Hemolysis at 100 µM | Human | South American Rattlesnake Crotalus Durissus Terrificus | α-Helix | NA | ||
| 27999446 | 2017 | ENFFKEIERAGQRIRDAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | WT | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 50 % Hemolysis at >115 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | ENFFKRIRRAGKRIRDAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM1 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 50 % Hemolysis at 1752.3 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | ENFFKRIRRAGKRIRDAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM1 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 2.3 % Hemolysis at 115 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | RNFFKRIRRAGKRIRKAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM2 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 50 % Hemolysis at 735.4 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | RNFFKRIRRAGKRIRKAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM2 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 6.88 % Hemolysis at 115 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 28408902 | 2017 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 4.47 (±0.35) % Hemolysis at 175 μg/ml | Human | Human Cathelicidin | α-Helix | NA | ||
| 28089718 | 2017 | GLFKKLRRKIKKGFKKIFKRLPPIGVGVSIPLAGKR | AM-CATH36 | Free | Free | Linear | L | None | 36 | Antimicrobial | 0 % Hemolysis at 300 μg/ml | Sheep | A. Mississippiensis | α-Helix | Non-hemolytic | ||
| 28089718 | 2017 | KRFKKFFKKLKNSVKKRAKKFFKKPKVIGVTFPF | AM-CATH | Free | Free | Linear | L | None | 34 | Antimicrobial | 0 % Hemolysis at 300 μg/ml | Sheep | A. Mississippiensis | α-Helix | Non-hemolytic | ||
| 28347740 | 2017 | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | ABP-dHC-Cecropin A | Free | Free | Linear | L | None | 37 | Antibacterial | 0 % Hemolysis at 1-800 µM | Human | Drury (Hyphantria Cunea) (Dhc) | α-Helix | Non-hemolytic | ||
| 28347740 | 2017 | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | ABP-dHC-Cecropin A-K(24) | Free | Free | Linear | L | None | 37 | Antibacterial | 0 % Hemolysis at 1-800 µM | Human | Abp-Dhc-Cecropin A Analog | α-Helix | Non-hemolytic | ||
| 28593346 | 2017 | ASENGKCNLLCLVKKKLRAVGNVIKTVVGKIA | Cathelicidin-PP | Free | Free | Linear | L | None | 32 | Antimicrobial | 5.65 % Hemolysis at 200 μg/ml | Rabbit | Tree Frog Polypedates Puerensis | β-Sheet | NA | ||
| 28630199 | 2017 | KRVKRFKKFFRKIKKGFRKIFKKTKIFIGGT | Pb-CATH1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 0 % Hemolysis at 4 μg/ml | Chicken | Python Bivittatus | α-Helix | Non-hemolytic | ||
| 28630199 | 2017 | KRVKRFKKFFRKIKKGFRKIFKKTKIFIGGT | Pb-CATH1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 1.4±0.4 % Hemolysis at 8 μg/ml | Chicken | Python Bivittatus | α-Helix | NA | ||
| 28630199 | 2017 | KRVKRFKKFFRKIKKGFRKIFKKTKIFIGGT | Pb-CATH1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 5.1±0.5 % Hemolysis at 16 μg/ml | Chicken | Python Bivittatus | α-Helix | NA | ||
| 28630199 | 2017 | KRVKRFKKFFRKIKKGFRKIFKKTKIFIGGT | Pb-CATH1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 7.3±0.6 % Hemolysis at 32 μg/ml | Chicken | Python Bivittatus | α-Helix | NA | ||
| 28630199 | 2017 | KRVKRFKKFFRKIKKGFRKIFKKTKIFIGGT | Pb-CATH1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 12.2±0.7 % Hemolysis at 64 μg/ml | Chicken | Python Bivittatus | α-Helix | NA | ||
| 28904355 | 2017 | NPEKALEPLIAIQIAIKGMLNGWFTGVGFRRKR | LysAB2 P0 | Free | Free | Linear | L | None | 33 | Antibacterial | 63.2 % Hemolysis at 64 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab2 | α-Helix | NA | ||
| 28904355 | 2017 | NPEKALEPLIAIQIAIKGMLNGWFTGVGFRRKR | LysAB2 P0 | Free | Free | Linear | L | None | 33 | Antibacterial | 100 % Hemolysis at 128 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab3 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P1 | Free | Free | Linear | L | None | 31 | Antibacterial | 50 % Hemolysis at 32 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab4 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P1 | Free | Free | Linear | L | None | 31 | Antibacterial | 60 % Hemolysis at 64 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab5 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P1 | Free | Free | Linear | L | None | 31 | Antibacterial | 80 % Hemolysis at 128 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab6 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLAGWFTGVGARRKR | LysAB2 P2 | Free | Free | Linear | L | None | 31 | Antibacterial | 90 % Hemolysis at 128 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab7 | α-Helix | NA | ||
| 28904355 | 2017 | NPEKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P3 | Free | Free | Linear | L | None | 33 | Antibacterial | 1.97 % Hemolysis at 4 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab8 | α-Helix | NA | ||
| 28904355 | 2017 | NPEKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P3 | Free | Free | Linear | L | None | 33 | Antibacterial | <10 % Hemolysis at 256 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab9 | α-Helix | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 58.5 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 28.1 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 8.4 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 4.3 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 85.3 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 67.1 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 40.1 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 23 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 11.9 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | <50 % Hemolysis at 10 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | <50 % Hemolysis at 20 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | <100 % Hemolysis at 50 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 20 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | <50 % Hemolysis at 50 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28483966 | 2017 | GGLKKLGKKLEGAGKRVFNAAEKALPVVAGAKALRK | cecropin A2 | Free | Free | Linear | L | None | 36 | Antimicrobial | 0 % Hemolysis at 60 μg/mL | Human | Aedes Aegypti Cecropin A | α-Helical | Non-hemolytic | ||
| 37892141 | 2023 | GLFGRLRDSLRRGGQKILEKVERIGDRIKDIFRG | MAP34-B | Free | Free | Linear | L | None | 34 | Antimicrobial | <0.5 % Hemolysis at 25 μg/mL | Mouse | Goat Submandibular Glands | α-Helical/Random curls | NA | ||
| 37892141 | 2023 | GLFGRLRDSLRRGGQKILEKVERIGDRIKDIFRG | MAP34-B | Free | Free | Linear | L | None | 34 | Antimicrobial | <0.5 % Hemolysis at 50 μg/mL | Mouse | Goat Submandibular Glands | α-Helical/Random curls | NA | ||
| 37892141 | 2023 | GLFGRLRDSLRRGGQKILEKVERIGDRIKDIFRG | MAP34-B | Free | Free | Linear | L | None | 34 | Antimicrobial | <0.5 % Hemolysis at 100 μg/mL | Mouse | Goat Submandibular Glands | α-Helical/Random curls | NA | ||
| 37892141 | 2023 | GLFGRLRDSLRRGGQKILEKVERIGDRIKDIFRG | MAP34-B | Free | Free | Linear | L | None | 34 | Antimicrobial | 0.68 % Hemolysis at 200 μg/mL | Mouse | Goat Submandibular Glands | α-Helical/Random curls | NA | ||
| 38139394 | 2023 | CIANRNGCQPDGSQGNCCSGYCHKEPGWVAGYR | Mak | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 5-100 μg/mL | mouse | Monochamus Alternatus | antiparallel β-Strands | Non-hemolytic | ||
| 38188573 | 2023 | GFGCPWDEMQCHNHCKSIKGYKGGYCAKGGFVCKCY | Ple-AB | Free | Free | Linear | L | None | 36 | Antimicrobial | 1.07 % Hemolysis at 0.5-256 μg/mL | Mouse | Derived From Plectasin | α-Helical | Non-hemolytic | ||
| 38276646 | 2024 | GFGCPWNRYQCHSHCRSIGRLGGYCAGSLRLTCTCYRS | American oyster defensin (AOD) | Free | Free | Linear | L | None | 38 | Antimicrobial | 1.29 % Hemolysis at 256 μg/mL | Mouse | Crassostrea Virginica | NA | NA | ||
| 38004789 | 2024 | KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVSFPF{ct:Amid} | Aquiluscidin | Amidation | Free | Linear | L | None | 34 | Antimicrobial | <2.3 % Hemolysis at | Rat | Crotalus Aquilus | α-Helical | NA | | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRAAFHGKKVAIVAINA{ct:Amid} | Analog 5 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | 14.1 % Hemolysis at 1024 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRAAFHGKKVAIVAINA{ct:Amid} | Analog 5 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | 11.8 % Hemolysis at 512 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIND{ct:Amid} | Analog 1(SJGAP) | Amidation | Free | Linear | L | None | 33 | Antimicrobial | <4 % Hemolysis at 1024 μg/mL | Horse | Skipjack Tuna Glyceraldehyde-3-Phosphate Dehydrogenase (Gapdh)-Related Peptide (Sjgap) | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRAAFHGKKVKIVAINK{ct:Amid} | Analog 6 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | 10 % Hemolysis at 1024 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRAAFHGKKVKIVAINK{ct:Amid} | Analog 6 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | <10 % Hemolysis at 512 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRLLFHGKKVEIVLIND{ct:Amid} | Analog 7 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | <10 % Hemolysis at 1024 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRLLFHGKKVEIVLIND{ct:Amid} | Analog 7 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | <6 % Hemolysis at 512 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIND{ct:Amid} | Analog 8 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | <6 % Hemolysis at 1024 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37760707 | 2024 | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIND{ct:Amid} | Analog 8 | Amidation | Free | Linear | L | None | 33 | Antimicrobial | 4 % Hemolysis at 512 μg/mL | Horse | Analog Of Sjgap | α-Helical | NA | ||
| 37907616 | 2024 | LIQRGRFGRFLGKIRHFRPRVKFNVHLRGSVGLG{ct:Amid} | Corvus CATH-2 | Amidation | Free | Linear | L | None | 38 | Antimicrobial | 22 % Hemolysis at 62.89 µM | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 39 | Antibacterial/ Antibiofilm | 5.4 % Hemolysis at 10 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 39 | Antibacterial/ Antibiofilm | 22 % Hemolysis at 100 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 29196622 | 2017 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial Agents and Chemotherapy | 10 % Hemolysis at >100 μM | Human | Human Neutrophils | α-Helical peptide | NA | ||
| 29196622 | 2017 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial Agents and Chemotherapy | 50 % Hemolysis at >100 μM | Human | Human Neutrophils | α-Helical peptide | NA | ||
| 29392557 | 2018 | KRFKKFFRKLKKSVKKRAKEFFKKPRVIGVSIPF | Cath-BF | Free | Free | Linear | L | None | 32 | Antimicrobial | 20 % Hemolysis at 500 μg/ml | Human | Snakes Naja Atra, Bugarus Fasciatus | NA | NA | ||
| 29392557 | 2018 | KRFKKFFRKLKKSVKKRKKEFKKKPRVIKVSIPF | Cath-A | Free | Free | Linear | L | None | 32 | Antimicrobial | 20 % Hemolysis at 500 μg/ml | Human | Snakes Naja Atra, Bugarus Fasciatus | α-Helix | NA | ||
| 29392557 | 2018 | KRFKKFFRKLKKSVKKRKKEFKKKPRVIGVSIPF | Cath-B | Free | Free | Linear | L | None | 32 | Antimicrobial | 5 % Hemolysis at 500 μg/ml | Human | Snakes Naja Atra, Bugarus Fasciatus | α-Helix | Low hemolytic | ||
| 29282543 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL37 | Amidation | Free | Linear | L | None | 37 | Antimicrobial | 8.6 % Hemolysis at 128 μM | Human | Homo Sapiens | NA | Low hemolytic | ||
| 29282543 | 2018 | VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR{ct:Amid} | NP-1 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0.72 % Hemolysis at 128 μM | Human | Rat (Rattus Norvegicus) | NA | Low hemolytic | ||
| 29282543 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL37 | Amidation | Free | Linear | L | None | 37 | Antimicrobial | ≥5 % Hemolysis at 64 μM | Human | Homo Sapiens | NA | Low hemolytic | ||
| 29282543 | 2018 | VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR{ct:Amid} | NP-1 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | ≥5 % Hemolysis at >128 μM | Human | Rat (Rattus Norvegicus) | NA | Low hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OtBu} | 11 | OtBu | Cbz | Linear | L | AzPro = azaproline, OtBu = ortho-tert-butyl, Cbz = carboxybenzyl | 32 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Hexadecameric Analogous Peptides | β 6.3-Helical | Non-hemolytic | ||
| 29307075 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES ({nnr:AcO−}) | LL-37 acetate | Free | Free | Linear | L | AcO− = Counter-ion acetate | 37 | Antimicrobial | ~4 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29307075 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES ({nnr:TFA−}) | LL-37 trifluoroacetate | Free | Free | Linear | L | TFA− = Counter-ion trifluoroacetate | 37 | Antimicrobial | ~4 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29307075 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES ({nnr:Cl−}) | LL-37 chloride | Free | Free | Linear | L | Cl− = Counter-ion chloride | 37 | Antimicrobial | ~4 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29501691 | 2018 | KWKIFKKIEKVGRNVRDGIIKAGPAVQVVGQATSIAK | DAN1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 200 µg/mL | Sheep | Danaus Plexippus (Monarch Butterfly) | NA | Non-hemolytic | ||
| 29501691 | 2018 | RWKFLKKIEKVGRKVRDGVIKAGPAVGVVGQATSIYK | DAN2 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 200 µg/mL | Sheep | Danaus Plexippus (Monarch Butterfly) | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY | Cap18 - pure | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 ± 1 % Hemolysis at 64 μg/ml | Horse | Rabbit Neutrophils | α-Helical | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY | Cap18 - library | Free | Free | Linear | L | None | 37 | Antimicrobial | 2 ± 1 % Hemolysis at 32 μg/ml | Horse | Rabbit Neutrophils | α-Helical | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRPRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFLNKIKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 2 | Free | Free | Linear | L | None | 37 | Antimicrobial | 6 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKDKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 3 | Free | Free | Linear | L | None | 37 | NA | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKFKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 4 | Free | Free | Linear | L | None | 37 | Antimicrobial | 2 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKHKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 5 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKMKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 6 | Free | Free | Linear | L | None | 37 | Antimicrobial | 2 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKQKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 7 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKSKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 8 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKECLKKIGQKIQGLLPKLAPRTDY | Peptide 9 | Free | Free | Linear | L | None | 37 | Antimicrobial | 4 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Low hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEDLKKIGQKIQGLLPKLAPRTDY | Peptide 10 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEFLKKIGQKIQGLLPKLAPRTDY | Peptide 11 | Free | Free | Linear | L | None | 37 | Antimicrobial | 9 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEILKKIGQKIQGLLPKLAPRTDY | Peptide 12 | Free | Free | Linear | L | None | 37 | Antimicrobial | 10 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKELLKKIGQKIQGLLPKLAPRTDY | Peptide 13 | Free | Free | Linear | L | None | 37 | Antimicrobial | 14 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEMLKKIGQKIQGLLPKLAPRTDY | Peptide 14 | Free | Free | Linear | L | None | 37 | Antimicrobial | 8 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEYLKKIGQKIQGLLPKLAPRTDY | Peptide 15 | Free | Free | Linear | L | None | 37 | Antimicrobial | 9 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKDKKIGQKIQGLLPKLAPRTDY | Peptide 16 | Free | Free | Linear | L | None | 37 | NA | 0 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKKKKIGQKIQGLLPKLAPRTDY | Peptide 17 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKPKKIGQKIQGLLPKLAPRTDY | Peptide 18 | Free | Free | Linear | L | None | 37 | NA | 0 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLPKIGQKIQGLLPKLAPRTDY | Peptide 19 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKEGQKIQGLLPKLAPRTDY | Peptide 20 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKHGQKIQGLLPKLAPRTDY | Peptide 21 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKNGQKIQGLLPKLAPRTDY | Peptide 22 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKICQKIQGLLPKLAPRTDY | Peptide 23 | Free | Free | Linear | L | None | 37 | Antimicrobial | 4 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Low hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKILQKIQGLLPKLAPRTDY | Peptide 24 | Free | Free | Linear | L | None | 37 | Antimicrobial | 7 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKCQGLLPKLAPRTDY | Peptide 25 | Free | Free | Linear | L | None | 37 | Antimicrobial | 2 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKDQGLLPKLAPRTDY | Peptide 26 | Free | Free | Linear | L | None | 37 | NA | 0 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKGQGLLPKLAPRTDY | Peptide 27 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKNQGLLPKLAPRTDY | Peptide 28 | Free | Free | Linear | L | None | 37 | NA | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKSQGLLPKLAPRTDY | Peptide 29 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQTLLPKLAPRTDY | Peptide 30 | Free | Free | Linear | L | None | 37 | Antimicrobial | 2 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGPLPKLAPRTDY | Peptide 31 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLAKLAPRTDY | Peptide 32 | Free | Free | Linear | L | None | 37 | Antimicrobial | 4 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Low hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLDKLAPRTDY | Peptide 33 | Free | Free | Linear | L | None | 37 | Antimicrobial | 3 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Low hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLFKLAPRTDY | Peptide 34 | Free | Free | Linear | L | None | 37 | Antimicrobial | 7 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | NA | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLHKLAPRTDY | Peptide 35 | Free | Free | Linear | L | None | 37 | Antimicrobial | 3 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Low hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKIQGLLSKLAPRTDY | Peptide 36 | Free | Free | Linear | L | None | 37 | Antimicrobial | 4 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Low hemolytic | ||
| 29859288 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 2.9±0.7 % Hemolysis at 500 μg/ml | Human | Human Cathelicidin-Derived Peptide | α-Helical | Low hemolytic | ||
| 30215282 | 2018 | QAFQTFKPDWNKIRYDAMKMQTSLGQMKKRFNL | Ltc 6a | Free | Free | Linear | L | None | 33 | Antibacterial | 20 % Hemolysis at >120 μM | Rabbit | Spider Lachesana Tarabaevi | water = Random coil, 50% trifluoroethano = α-helice | NA | ||
| 30215282 | 2018 | GETFDKLKEKLKTFYQKLVEKAEDLKGDLKAKLS | Ltc 7 | Free | Free | Linear | L | None | 34 | Antibacterial | 20 % Hemolysis at >120 μM | Rabbit | Spider Lachesana Tarabaevi | water = Random coil, 50% trifluoroethano = α-helice | NA | ||
| 30279591 | 2018 | GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS | Sushi 1 Wild Type | Free | Free | Linear | L | None | 34 | Antibacterial | 100 % Hemolysis at 50 μM | Human | Horseshoe Crabs | aqueous = Random coil + Extended Strand, PBS = Random coil | NA | ||
| 30279591 | 2018 | GFGLGGLARILCLGNRQWSNFFKKLNRKCAMVKK | SRP-1 | Free | Free | Linear | L | None | 34 | Antibacterial | 0 % Hemolysis at 50 μM | Human | Designed From Horseshoe Crab Peptide | aqueous = α-Helix | Non-hemolytic | ||
| 30279591 | 2018 | GFALAGLARILCLWFREFSGFFRRLNRRFAMRRR | SRP-2 | Free | Free | Linear | L | None | 34 | Antibacterial | 0 % Hemolysis at 50 μM | Human | Designed From Horseshoe Crab Peptide | aqueous = α-Helix, 50% TFE = α-Helix | Non-hemolytic | ||
| 30279591 | 2018 | GAALAGLAKILCLWAKEFTGAFKKLNKKFAMKKK | SRP-3 | Free | Free | Linear | L | None | 34 | Antibacterial | 100 % Hemolysis at 50 μM | Human | Designed From Horseshoe Crab Peptide | aqueous = α-Helix | NA | ||
| 30360541 | 2018 | GFWSSVWDGAKNVGTAIIKNAKVCVYAVCVSHK | Nicomicin-1 | Free | Free | Linear | L | None | 33 | Antibacterial | 50 % Hemolysis at 64 µM | Human | Polychaeta Tubeworm Nicomache Minor | aqueous = Disordered, Membrane-Mimicking Environment = α-Helix | NA | ||
| 30462698 | 2018 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK | PACAP38 | Free | Free | Linear | L | None | 38 | Antibacterial | 0 % Hemolysis at 45 μg/mL | Human | Human | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | GWGSIFKTVGKMIAKAAVKAAPEAISAMASQNE | PLP2 | Free | Free | Linear | L | None | 33 | Antimicrobial, histamine-releasing activity | 10.4 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | NA | ||
| 30658410 | 2019 | KIKWGKIFKKGGKLIGKTALEAAANAAASEAISAMASQNE | PLP3 | Free | Free | Linear | L | None | 40 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | IKGKKIMKNMGKAMKIAGKVAKAMAPIVVPLIVSAA{ct:Amid} | PLP6 | Amidation | Free | Linear | L | None | 36 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | GWGSIFKTVGKMIAKAAVKAAPEAISAMASQNE | PLP2 | Free | Free | Linear | L | None | 33 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | KIKWGKIFKKGGKLIGKTALEAAANAAASEAISAMASQNE | PLP3 | Free | Free | Linear | L | None | 40 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | IKGKKIMKNMGKAMKIAGKVAKAMAPIVVPLIVSAA{ct:Amid} | PLP6 | Amidation | Free | Linear | L | None | 36 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30701481 | 2019 | GLPLLISWIKRKRQQGSKKPVPIIYCNRRTGKCQRM | Hybrid Peptide | Free | Free | Linear | L | None | 36 | Antibacterial, Anticancer | 0 % Hemolysis at 45 μmol/L | Sheep | Mutant Fragments Of Melittin And Thanatin | x | Non-hemolytic | ||
| 30607494 | 2019 | KWKLFKKIHKVGQNIRKGIIKAGPAVAVVGQAAQIAK | PEW300 | Free | Free | Linear | L | None | 37 | Antibacterial | 0 % Hemolysis at 224 μg/ml | Sheep | Synthetic Cecropin A-Derived | α-Helix | Non-hemolytic | ||
| 30476118 | 2019 | FTKIIHKLKKFIRYRKVLRWSRMWWVLLVREIVGDN{ct:Amid} | EXP2-HD | Amidation | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 10.71 µM | Human | Synthetic Peptide | NA | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 0 % Hemolysis at 18.75 µM | Fish | Catfish Clarias Gariepinus | α-Helix | Non-hemolytic | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | <20 % Hemolysis at 150 µM | Fish | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 39 % Hemolysis at 300 µM | Fish | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 0 % Hemolysis at 75 µM | Human | Catfish Clarias Gariepinus | α-Helix | Non-hemolytic | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | <3 % Hemolysis at 150 µM | Human | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 6 % Hemolysis at 300 µM | Human | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30886247 | 2019 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antibacterial | 30 % Hemolysis at 40 µM | Porcine | Human | α-Helix | NA | ||
| 30886247 | 2019 | GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG{nt:Acet} | PMAP-36 | Free | Acetylation | Linear | L | None | 36 | Antibacterial | <10 % Hemolysis at 40 µM | Porcine | Porcine Cathelicidin | α-Helix | NA | ||
| 31016971 | 2019 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | cathelicidin LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 5 % Hemolysis at 10 µM | Human | Homo Sapiens (Human) Cathelicidin Amp | α-Helix | Low hemolytic | ||
| 31016971 | 2019 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNL | Fragment LL-32 | Free | Free | Linear | L | None | 32 | Antimicrobial | 40 % Hemolysis at 10 µM | Human | Fragment Of Cathelicidin Ll-37 | α-Helix | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYGYGRKKRRQRR | HA2-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 2.3 ± 0.5 (n at 10) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | INF7-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 1.4 ± 0.4 (n at 10) µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | pH 5.5 = α-Helix | NA | ||
| 31159194 | 2019 | CGLFHAIAHFIHGGWHGLIHGWYGYGRKKRRQRR | H5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 5.9 µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFKAIAKFIKGGWKGLIKGWYGYGRKKRRQRR | K5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 1.9 µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | E5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CRLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12c | Free | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C({nnr:Nle})LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12d | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CVLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.72 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12f | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 0.38 ± 0.17 (n at 5) µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CSLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGKFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGEFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGNFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLNEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLGEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLKEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLEEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14e | Free | Free | Linear | L | None | 34 | NA | ~65 % Hemolysis at 1.3 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLLEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.93 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFAAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFNAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.12 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFLAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFKAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFENIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFELIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.23 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEKIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAKEGFIENGWEGMIDGWYGYGRKKRRQRR | 17a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAEEGFIENGWEGMIDGWYGYGRKKRRQRR | 17b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.74 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEALEGFIENGWEGMIDGWYGYGRKKRRQRR | 17c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIWGFIENGWEGMIDGWYGYGRKKRRQRR | 18a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.9 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIKGFIENGWEGMIDGWYGYGRKKRRQRR | 18b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIHGFIENGWEGMIDGWYGYGRKKRRQRR | 18c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIRGFIENGWEGMIDGWYGYGRKKRRQRR | 18d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIDGFIENGWEGMIDGWYGYGRKKRRQRR | 18e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIGGFIENGWEGMIDGWYGYGRKKRRQRR | 18f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIENFIENGWEGMIDGWYGYGRKKRRQRR | 19a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEKFIENGWEGMIDGWYGYGRKKRRQRR | 19b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.32 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEEFIENGWEGMIDGWYGYGRKKRRQRR | 19c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.41 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 19d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 20c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFGENGWEGMIDGWYGYGRKKRRQRR | 21a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFAENGWEGMIDGWYGYGRKKRRQRR | 21b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.59 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFLENGWEGMIDGWYGYGRKKRRQRR | 21c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.59 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFWENGWEGMIDGWYGYGRKKRRQRR | 21d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFKENGWEGMIDGWYGYGRKKRRQRR | 21e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFNENGWEGMIDGWYGYGRKKRRQRR | 21f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFILNGWEGMIDGWYGYGRKKRRQRR | 22a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.06 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIWNGWEGMIDGWYGYGRKKRRQRR | 22b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.44 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIKNGWEGMIDGWYGYGRKKRRQRR | 22c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.27 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIGNGWEGMIDGWYGYGRKKRRQRR | 22d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.16 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEGGWEGMIDGWYGYGRKKRRQRR | 23c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.11 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIELGWEGMIDGWYGYGRKKRRQRR | 23d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.34 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEWGWEGMIDGWYGYGRKKRRQRR | 23e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.54 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEKGWEGMIDGWYGYGRKKRRQRR | 23f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENEWEGMIDGWYGYGRKKRRQRR | 24a | Free | Free | Linear | L | None | 34 | NA | ~45 % Hemolysis at 2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENKWEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENNWEGMIDGWYGYGRKKRRQRR | 24c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.39 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENHWEGMIDGWYGYGRKKRRQRR | 24d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.06 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENPWEGMIDGWYGYGRKKRRQRR | 24e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENAWEGMIDGWYGYGRKKRRQRR | 24f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENWWEGMIDGWYGYGRKKRRQRR | 24g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGEEGMIDGWYGYGRKKRRQRR | 25a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.55 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGKEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLEGMIDGWYGYGRKKRRQRR | 25c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWDGMIDGWYGYGRKKRRQRR | 26a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.55 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWRGMIDGWYGYGRKKRRQRR | 26b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.19 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDGWYGYGRKKRRQRR | 26c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.34 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWHGMIDGWYGYGRKKRRQRR | 26d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.54 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWNGMIDGWYGYGRKKRRQRR | 26e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.47 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWLGMIDGWYGYGRKKRRQRR | 26f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.84 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWAGMIDGWYGYGRKKRRQRR | 26g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.3 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWGGMIDGWYGYGRKKRRQRR | 26h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEAMIDGWYGYGRKKRRQRR | 27a | Free | Free | Linear | L | None | 34 | NA | ~65 % Hemolysis at 0.12 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWENMIDGWYGYGRKKRRQRR | 27b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.42 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEKMIDGWYGYGRKKRRQRR | 27c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.01 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEEMIDGWYGYGRKKRRQRR | 27d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.76 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:M sulfoxide})IDGWYGYGRKKRRQRR | 28a | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG{nnr:M sulfone}IDGWYGYGRKKRRQRR | 28b | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGNIDGWYGYGRKKRRQRR | 28c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGQIDGWYGYGRKKRRQRR | 28d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGTIDGWYGYGRKKRRQRR | 28e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGSIDGWYGYGRKKRRQRR | 28f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 28g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:Nle})IDGWYGYGRKKRRQRR | 28h | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 0.53 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGYIDGWYGYGRKKRRQRR | 28i | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.56 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGFIDGWYGYGRKKRRQRR | 28j | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGIDGWYGYGRKKRRQRR | 28k | Free | Free | Linear | L | delete | 33 | NA | 50 % Hemolysis at 50 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMLDGWYGYGRKKRRQRR | 29a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 10.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMADGWYGYGRKKRRQRR | 29b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMGDGWYGYGRKKRRQRR | 29c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.53 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMNDGWYGYGRKKRRQRR | 29d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMKDGWYGYGRKKRRQRR | 29e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.17 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMEDGWYGYGRKKRRQRR | 29f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIEGWYGYGRKKRRQRR | 30a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIAGWYGYGRKKRRQRR | 30b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIWGWYGYGRKKRRQRR | 30c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMILGWYGYGRKKRRQRR | 30d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDAWYGYGRKKRRQRR | 31a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDLWYGYGRKKRRQRR | 31b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.32 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDIWYGYGRKKRRQRR | 31c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.68 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDWWYGYGRKKRRQRR | 31d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.55 ± 0.25 (n at 8) µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDNWYGYGRKKRRQRR | 31e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.07 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDKWYGYGRKKRRQRR | 31f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.86 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDEWYGYGRKKRRQRR | 31g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGYGRKKRRQRR | 32a | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGGGYGRKKRRQRR | 32b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGLYGYGRKKRRQRR | 33a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGAYGYGRKKRRQRR | 33b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.07 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGYGYGRKKRRQRR | 33c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGNYGYGRKKRRQRR | 33d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGKYGYGRKKRRQRR | 33e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.6 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGEYGYGRKKRRQRR | 33f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWAGYGRKKRRQRR | 34a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWHGYGRKKRRQRR | 34b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWNGYGRKKRRQRR | 34c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.13 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWEGYGRKKRRQRR | 34d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.94 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYAYGRKKRRQRR | 35a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYWYGRKKRRQRR | 35b | Free | Free | Linear | L | None | 34 | NA | ~70 % Hemolysis at 0.17 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYEYGRKKRRQRR | 35c | Free | Free | Linear | L | None | 34 | NA | ~60% % Hemolysis at 1.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGCYGRKKRRQRR | 36a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.09 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 36b | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.7 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 3})YGRKKRRQRR | 36c | Free | Free | Linear | L | Peg 3 = Peg 3 | 34 | NA | 50 % Hemolysis at 1.92 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 6})YGRKKRRQRR | 36d | Free | Free | Linear | L | Peg 6 = Peg 6 | 34 | NA | 50 % Hemolysis at 1.22 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg11})YGRKKRRQRR | 36e | Free | Free | Linear | L | Peg11 = Peg11 | 34 | NA | 50 % Hemolysis at 2.4 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 27})YGRKKRRQRR | 36f | Free | Free | Linear | L | Peg 27 = Peg 27 | 34 | NA | 50 % Hemolysis at 28 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGKKKKKQKK | 37a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.78 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHH | 37b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.90 ± 0.19 (n at 8) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRR | 37c | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 1.77 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQR | 37d | Free | Free | Linear | L | None | 33 | NA | 50 % Hemolysis at 0.75 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQ | 37e | Free | Free | Linear | L | None | 32 | NA | 50 % Hemolysis at 0.96 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRR | 37f | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at 1.61 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHR | 37h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.58 ± 0.17 (n at 10) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC | 38a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.96 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | YGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYGC | 38b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.91 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYG | 38c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.17 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d}C{d} | 38d | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 5 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d} | 38e | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 0.1 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}G{d}L{d}F{d}E{d}A{d}I{d}E{d}G{d}F{d}I{d}E{d}N{d}G{d}W{d}E{d}G{d}M{d}I{d}D{d}G{d}W{d}Y{d}G{d}Y{d}G{d}R{d}K{d}K{d}R{d}R{d}Q{d}R{d}R{d} | 38f | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 2.3 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRK{ct:stearoyl} | 39d | stearoyl | Free | Linear | L | stearoyl = stearoyl | 35 | NA | 50 % Hemolysis at 0.58 ± 0.2 (n at6) µM (pH 5.5) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC{nt:stearoyl} | 39e | Free | stearoyl | Linear | L | stearoyl = stearoyl | 34 | NA | 50 % Hemolysis at 0.7 µM (pH 5.5) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 40 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.12 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 41 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.41 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDWWYGYGRKKRRQRR | 42 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDAWYGYGRKKRRQRR | 43 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.62 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 44 | Free | Free | Linear | L | None | 37 | NA | ~50 % Hemolysis at 1 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 45 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 2.98 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CRLFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 46 | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 47 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 1.55 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGLIDWWYGYGRKKRRQRR | 48 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.72 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIWGFIENGWEGLIDGWYGYGRKKRRQRR | 49 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 50 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 2 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 51 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 52 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.1 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 53 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.18 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 54 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 55 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGIFGAIEGFIENGWWGLIDAWYGYGRKKRRQRR | 56 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.07 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 57 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.17 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGLKGLIDWWYGYGRKKRRQRR | 58 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.06 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | 59 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.79 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}GFEFIEEFIENGLKNLIDWWYGYGRKKRRQRR | 60 | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 1.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGRKKRRQRR | 61 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.97 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 62 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.28 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGRKKRRQRR | 63 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.6 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGHKKHHQHR | 64 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.91 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGLENLIDWWYGYGRKKRRQRR | 65 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.15 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGWENFIDWWYGYGRKKRRQRR | 66 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.08 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGWEGLIDWWYGYGRKKRRQRR | 67 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.4 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGRKKRRQRR | 68 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.11 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGHKKHHQHR | 69 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.73 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 70 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.28 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYGYGRKKRRQRR | HA2-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 5.7 ± 1.1 (n at 10) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | INF7-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 4.6 ± 1.2 (n at 10) µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | pH 7.4 = Random coil | NA | ||
| 31159194 | 2019 | CGLFHAIAHFIHGGWHGLIHGWYGYGRKKRRQRR | H5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 0.3 µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFKAIAKFIKGGWKGLIKGWYGYGRKKRRQRR | K5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | E5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 2.2 µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CRLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12c | Free | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C({nnr:Nle})LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12d | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 2.4 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CVLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12f | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at >20 (n at 5) µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CSLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.16 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGKFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGEFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGNFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLNEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLGEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLKEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLEEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLLEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.67 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFAAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.75 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFNAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.78 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFLAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFKAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.27 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFENIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFELIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.93 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEKIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.11 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAKEGFIENGWEGMIDGWYGYGRKKRRQRR | 17a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAEEGFIENGWEGMIDGWYGYGRKKRRQRR | 17b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEALEGFIENGWEGMIDGWYGYGRKKRRQRR | 17c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIWGFIENGWEGMIDGWYGYGRKKRRQRR | 18a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.2 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIKGFIENGWEGMIDGWYGYGRKKRRQRR | 18b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIHGFIENGWEGMIDGWYGYGRKKRRQRR | 18c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >80 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIRGFIENGWEGMIDGWYGYGRKKRRQRR | 18d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.8 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIDGFIENGWEGMIDGWYGYGRKKRRQRR | 18e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIGGFIENGWEGMIDGWYGYGRKKRRQRR | 18f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIENFIENGWEGMIDGWYGYGRKKRRQRR | 19a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.09 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEKFIENGWEGMIDGWYGYGRKKRRQRR | 19b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEEFIENGWEGMIDGWYGYGRKKRRQRR | 19c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 19d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.71 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.97 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 20c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.71 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.97 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFGENGWEGMIDGWYGYGRKKRRQRR | 21a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFAENGWEGMIDGWYGYGRKKRRQRR | 21b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFLENGWEGMIDGWYGYGRKKRRQRR | 21c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.8 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFWENGWEGMIDGWYGYGRKKRRQRR | 21d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFKENGWEGMIDGWYGYGRKKRRQRR | 21e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFNENGWEGMIDGWYGYGRKKRRQRR | 21f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFILNGWEGMIDGWYGYGRKKRRQRR | 22a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIWNGWEGMIDGWYGYGRKKRRQRR | 22b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.95 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIKNGWEGMIDGWYGYGRKKRRQRR | 22c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIGNGWEGMIDGWYGYGRKKRRQRR | 22d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEGGWEGMIDGWYGYGRKKRRQRR | 23c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.55 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIELGWEGMIDGWYGYGRKKRRQRR | 23d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.31 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEWGWEGMIDGWYGYGRKKRRQRR | 23e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5.18 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEKGWEGMIDGWYGYGRKKRRQRR | 23f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENEWEGMIDGWYGYGRKKRRQRR | 24a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENKWEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENNWEGMIDGWYGYGRKKRRQRR | 24c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENHWEGMIDGWYGYGRKKRRQRR | 24d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENPWEGMIDGWYGYGRKKRRQRR | 24e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.72 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENAWEGMIDGWYGYGRKKRRQRR | 24f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.28 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENWWEGMIDGWYGYGRKKRRQRR | 24g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGEEGMIDGWYGYGRKKRRQRR | 25a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.31 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGKEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLEGMIDGWYGYGRKKRRQRR | 25c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.43 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWDGMIDGWYGYGRKKRRQRR | 26a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.3 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWRGMIDGWYGYGRKKRRQRR | 26b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.3 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDGWYGYGRKKRRQRR | 26c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWHGMIDGWYGYGRKKRRQRR | 26d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWNGMIDGWYGYGRKKRRQRR | 26e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWLGMIDGWYGYGRKKRRQRR | 26f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.03 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWAGMIDGWYGYGRKKRRQRR | 26g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWGGMIDGWYGYGRKKRRQRR | 26h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEAMIDGWYGYGRKKRRQRR | 27a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.95 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWENMIDGWYGYGRKKRRQRR | 27b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEKMIDGWYGYGRKKRRQRR | 27c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.99 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEEMIDGWYGYGRKKRRQRR | 27d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:M sulfoxide})IDGWYGYGRKKRRQRR | 28a | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG(M sulfone)IDGWYGYGRKKRRQRR | 28b | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGNIDGWYGYGRKKRRQRR | 28c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGQIDGWYGYGRKKRRQRR | 28d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGTIDGWYGYGRKKRRQRR | 28e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGSIDGWYGYGRKKRRQRR | 28f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 28g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:Nle})IDGWYGYGRKKRRQRR | 28h | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 3.94 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGYIDGWYGYGRKKRRQRR | 28i | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGFIDGWYGYGRKKRRQRR | 28j | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 9.65 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGIDGWYGYGRKKRRQRR | 28k | Free | Free | Linear | L | delete | 33 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMLDGWYGYGRKKRRQRR | 29a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMADGWYGYGRKKRRQRR | 29b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMGDGWYGYGRKKRRQRR | 29c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMNDGWYGYGRKKRRQRR | 29d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMKDGWYGYGRKKRRQRR | 29e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 9.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMEDGWYGYGRKKRRQRR | 29f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIEGWYGYGRKKRRQRR | 30a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIAGWYGYGRKKRRQRR | 30b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.83 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIWGWYGYGRKKRRQRR | 30c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMILGWYGYGRKKRRQRR | 30d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDAWYGYGRKKRRQRR | 31a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDLWYGYGRKKRRQRR | 31b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.96 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDIWYGYGRKKRRQRR | 31c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDWWYGYGRKKRRQRR | 31d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.14 ± 0.73 (n at 8) µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDNWYGYGRKKRRQRR | 31e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.26 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDKWYGYGRKKRRQRR | 31f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDEWYGYGRKKRRQRR | 31g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGYGRKKRRQRR | 32a | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGGGYGRKKRRQRR | 32b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGLYGYGRKKRRQRR | 33a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.75 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGAYGYGRKKRRQRR | 33b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGYGYGRKKRRQRR | 33c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGNYGYGRKKRRQRR | 33d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGKYGYGRKKRRQRR | 33e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGEYGYGRKKRRQRR | 33f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWAGYGRKKRRQRR | 34a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWHGYGRKKRRQRR | 34b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWNGYGRKKRRQRR | 34c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.72 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWEGYGRKKRRQRR | 34d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYAYGRKKRRQRR | 35a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYWYGRKKRRQRR | 35b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.05 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYEYGRKKRRQRR | 35c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGCYGRKKRRQRR | 36a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 36b | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 7.9 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 3})YGRKKRRQRR | 36c | Free | Free | Linear | L | Peg 3 = Peg 3 | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 6})YGRKKRRQRR | 36d | Free | Free | Linear | L | Peg 6 = Peg 6 | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg11})YGRKKRRQRR | 36e | Free | Free | Linear | L | Peg11 = Peg11 | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 27})YGRKKRRQRR | 36f | Free | Free | Linear | L | Peg 27 = Peg 27 | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGKKKKKQKK | 37a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHH | 37b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 (n at 8) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRR | 37c | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 6.82 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQR | 37d | Free | Free | Linear | L | None | 33 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQ | 37e | Free | Free | Linear | L | None | 32 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRR | 37f | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHR | 37h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 (n at 10) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC | 38a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | YGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYGC | 38b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYG | 38c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d}C{d} | 38d | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d} | 38e | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 1.51 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}G{d}L{d}F{d}E{d}A{d}I{d}E{d}G{d}F{d}I{d}E{d}N{d}G{d}W{d}E{d}G{d}M{d}I{d}D{d}G{d}W{d}Y{d}G{d}Y{d}G{d}R{d}K{d}K{d}R{d}R{d}Q{d}R{d}R{d} | 38f | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRK(Stearoyl){ct:stearoyl} | 39d | stearoyl | Free | Linear | L | stearoyl = stearoyl | 35 | NA | 50 % Hemolysis at 0.94 ± 0.4 (n at 6) µM (pH 7.4) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC{nt:stearoyl} | 39e | Free | stearoyl | Linear | L | stearoyl = stearoyl | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 40 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 41 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDWWYGYGRKKRRQRR | 42 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDAWYGYGRKKRRQRR | 43 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 44 | Free | Free | Linear | L | None | 37 | NA | ~60 % Hemolysis at 5 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 45 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 4.32 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CRLFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 46 | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.12 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 47 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 3.97 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGLIDWWYGYGRKKRRQRR | 48 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIWGFIENGWEGLIDGWYGYGRKKRRQRR | 49 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 50 | Free | Free | Linear | L | None | 35 | NA | ~35 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 51 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 52 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.41 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 53 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 54 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 55 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.19 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGIFGAIEGFIENGWWGLIDAWYGYGRKKRRQRR | 56 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.35 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 57 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.99 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGLKGLIDWWYGYGRKKRRQRR | 58 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | 59 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}GFEFIEEFIENGLKNLIDWWYGYGRKKRRQRR | 60 | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 12.8 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGRKKRRQRR | 61 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.07 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 62 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGRKKRRQRR | 63 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGHKKHHQHR | 64 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGLENLIDWWYGYGRKKRRQRR | 65 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGWENFIDWWYGYGRKKRRQRR | 66 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGWEGLIDWWYGYGRKKRRQRR | 67 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGRKKRRQRR | 68 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGHKKHHQHR | 69 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 70 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31001677 | 2019 | EWRPHGSIGGSGLRPGRPQTLPPQRPRRPDFNGPRHRF | LSer-PRP2 | Free | Free | Linear | L | None | 38 | Antiparasitic | <20 % Hemolysis at 100 μM | Mouse | Lucilia Sericata | NA | NA | ||
| 31001677 | 2019 | SPFVDRPRRPIQHNGPKPRIITNPPFNPNARPAW | LSer-PRP3 | Free | Free | Linear | L | None | 34 | Antiparasitic | <20 % Hemolysis at 100 μM | Mouse | Lucilia Sericata | NA | NA | ||
| 31001677 | 2019 | KWKIFKKIEKAGRNIRDGIIKAGPAVSVVGEAATIYKTG | CecA | Free | Free | Linear | L | None | 39 | Antiparasitic | <20 % Hemolysis at 100 μM | Mouse | Galleria Mellonella | NA | NA | ||
| 31001677 | 2019 | KWKFFKKIERVGQNIRDGIIKAGPAVQVVGQAATIYKGK | CecB | Free | Free | Linear | L | None | 39 | Antiparasitic | <20 % Hemolysis at 100 μM | Mouse | Galleria Mellonella | NA | Low hemolytic | ||
| 31001677 | 2019 | RWKVFKKIERMGQHIRDGIIKAGPAVAVVGQASTIISG | CecC | Free | Free | Linear | L | None | 38 | Antiparasitic | <20 % Hemolysis at 100 μM | Mouse | Galleria Mellonella | NA | NA | ||
| 31001677 | 2019 | ENFFKEIERAGQRIRDAIISAAPAVETLAQAQKIIKGGD | CecD | Free | Free | Linear | L | None | 39 | Antiparasitic | <20 % Hemolysis at 100 μM | Mouse | Galleria Mellonella | NA | NA | ||
| 31001677 | 2019 | EWRPHGSIGGSGLRPGRPQTLPPQRPRRPDFNGPRHRF | LSer-PRP2 | Free | Free | Linear | L | None | 38 | Antiparasitic | <20 % Hemolysis at 100 μM | Pig | Lucilia Sericata | low hemolytic | NA | ||
| 31001677 | 2019 | SPFVDRPRRPIQHNGPKPRIITNPPFNPNARPAW | LSer-PRP3 | Free | Free | Linear | L | None | 34 | Antiparasitic | <20 % Hemolysis at 100 μM | Pig | Lucilia Sericata | low hemolytic | NA | ||
| 31001677 | 2019 | KWKIFKKIEKAGRNIRDGIIKAGPAVSVVGEAATIYKTG | CecA | Free | Free | Linear | L | None | 39 | Antiparasitic | <20 % Hemolysis at 100 μM | Pig | Galleria Mellonella | low hemolytic | NA | ||
| 31001677 | 2019 | KWKFFKKIERVGQNIRDGIIKAGPAVQVVGQAATIYKGK | CecB | Free | Free | Linear | L | None | 39 | Antiparasitic | <20 % Hemolysis at 100 μM | Pig | Galleria Mellonella | NA | Low hemolytic | ||
| 31001677 | 2019 | RWKVFKKIERMGQHIRDGIIKAGPAVAVVGQASTIISG | CecC | Free | Free | Linear | L | None | 38 | Antiparasitic | <20 % Hemolysis at 100 μM | Pig | Galleria Mellonella | NA | NA | ||
| 31001677 | 2019 | ENFFKEIERAGQRIRDAIISAAPAVETLAQAQKIIKGGD | CecD | Free | Free | Linear | L | None | 39 | Antiparasitic | <20 % Hemolysis at 100 μM | Pig | Galleria Mellonella | NA | NA | ||
| 31242693 | 2019 | SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGCRT{ct:OH} | Ranatuerin-2Pb | OH | Free | Linear | L | None | 34 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 16.11 μM | Horse | Frog Rana Pipiens | 50% TFE/H2O = α-Helix, membrane mimicking liposomes(POPC/POPG 1:1, POPE/POPG 3:1 ) = α-Helix | NA | ||
| 31242693 | 2019 | SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGC{ct:OH} | RPa | OH | Free | Linear | L | None | 32 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 63.9 μM | Horse | Truncated Analogues Of Ranatuerin-2Pb | 50% TFE/H2O = α-Helix, membrane mimicking liposomes(POPC/POPG 1:1, POPE/POPG 3:1 ) = α-Helix | NA | ||
| 31242693 | 2019 | SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGCRT{ct:OH} | Ranatuerin-2Pb | OH | Free | Linear | L | None | 34 | Antimicrobial, Antibiofilm | 20 % Hemolysis at 8 μM | Horse | Frog Rana Pipiens | 50% TFE/H2O = α-Helix, membrane mimicking liposomes(POPC/POPG 1:1, POPE/POPG 3:1 ) = α-Helix | NA | ||
| 31242693 | 2019 | SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGC{ct:OH} | RPa | OH | Free | Linear | L | None | 32 | Antimicrobial, Antibiofilm | 20 % Hemolysis at 32 μM | Horse | Truncated Analogues Of Ranatuerin-2Pb | 50% TFE/H2O = α-Helix, membrane mimicking liposomes(POPC/POPG 1:1, POPE/POPG 3:1 ) = α-Helix | NA | ||
| 31319057 | 2019 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 170 μM | Human | Human Innate Immune Peptide Ll-37 | α-Helix | NA | ||
| 31489876 | 2019 | GFGGGRGGFGGGRGGFGGGGIGGGGFGGGYGGGKIKG{ct:Amid} | Serrulin | Amidation | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 60 µg/mL | Human | Tityus Serrulatus (Brazilian Scorpion) | NA | Non-hemolytic | ||
| 31671555 | 2019 | ASWKVFLKNIGKAAGKAVLNSVTDMVNQ{ct:Amid} | Dermaseptin-SP2 | Amidation | Free | Linear | L | None | 31 | Antimicrobial | <4 % Hemolysis at 64 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | Non-hemolytic | ||
| 31671555 | 2019 | ASWKVFLKNIGKAAGKAVLNSVTDMVNQ{ct:Amid} | Dermaseptin-SP2 | Amidation | Free | Linear | L | None | 31 | Antimicrobial | >10 % Hemolysis at 256 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | NA | ||
| 32153522 | 2020 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at >80 μM | Human | Human Host Defense Peptide | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153522 | 2020 | AGGKRIVQRIKDFLRGAGGKRIVQRIKDFLRG{cyc:N-C} | cd4 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 50 % Hemolysis at >40 μM | Human | Cyclized Kr-12 Dimer | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153522 | 2020 | AGGKRIVKRIKKFLRGAGGKRIVKRIKKFLRG{cyc:N-C} | cd4(Q5K,D9K) | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 50 % Hemolysis at 10 μM | Human | Cyclized Kr-12 Dimer | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153547 | 2020 | RPLNFKMLRFWGQQQCRRPLYCRRRWSHPQFEK | X1-NCR247C-StrepII | Free | Free | Linear | L | None | 33 | Antibacterial | 3.51 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRRKALAALAKKILWSHPQFEK | NCR247C-X2-StrepII | Free | Free | Linear | L | None | 31 | Antibacterial | 11.4 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 32153547 | 2020 | RPLNFKMLRFWGQQQCRRPLYCRRRWSHPQFEK | X1-NCR247C-StrepII | Free | Free | Linear | L | None | 33 | Antibacterial | 1.75 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRRKALAALAKKILWSHPQFEK | NCR247C-X2-StrepII | Free | Free | Linear | L | None | 31 | Antibacterial | 6.14 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 32350599 | 2020 | RFRRLRWKTRWRLKKIRFGRFLRKIRRFRPK{ct:Amid} | PR-FO | Amidation | Free | Linear | L | None | 31 | Antibacterial | 10 % Hemolysis at 128 μM | Human | Hybrid Peptide Of Prw4 And Fowlicidin-2 | α-Helix | Low hemolytic | ||
| 33084564 | 2020 | KRFKKFFKKLKNSVKKRAKKFFKKPKVIGVTFPF | NACATH | Free | Free | Linear | L | None | 34 | Antibacterial | <10 % Hemolysis at 100 μg/ml | Sheep | Cathelicidin Peptide From The Chinese Cobra | Helical | Non-hemolytic | ||
| 33138816 | 2020 | GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSEFFQS | PMAP-37 | Free | Free | Linear | L | None | 37 | Antibacterial | <5 % Hemolysis at 1280 μg/ml | Mouse | Porcine Myeloma Cells | α-Helix | Non-hemolytic | ||
| 33138816 | 2020 | GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSERFQS | PMAP-37(F34-R) | Free | Free | Linear | L | None | 37 | Antibacterial | <5 % Hemolysis at 1280 μg/ml | Mouse | Modified Pmap-37 | NA | Non-hemolytic | ||
| 33138816 | 2020 | GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSERFQS{nt:Chol} | Chol-37(F34-R) | Free | Chol | Linear | L | Chol = cholesterol | 37 | Antibacterial, Wound healing and abscess reduction | <5 % Hemolysis at 1280 μg/ml | Mouse | Addition Of Cholesterol | NA | Non-hemolytic | ||
| 33495505 | 2021 | VRNSQSCRRNKGICVPIRCPGSMRQIGTCLGAQVKCCRRK | cystine dense peptide CDP-B11 | Free | Free | Linear | L | None | 40 | Antibacterial | 0 % Hemolysis at 200 μg/mL | Sheep | Bubalus Bubalis (Domestic Water Buffalo) | NA | Non-hemolytic | ||
| 33532575 | 2021 | KLKLKLKLKLKLKLKLKKLKKLKKLKKLKKLKKLKKL | L-G3KL | Free | Free | Branched | L | None | 37 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d} | D-G3KL | Free | Free | Branched | D | None | 37 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | KLKLKLKLKLKLKLKLKKLKKLKKLKKLKLLKLLKKLL | L-T25 | Free | Free | Branched | L | None | 38 | Antibacterial. Antibiofilm | MHC at 62.5 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | NA | ||
| 33532575 | 2021 | K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}L{d}L{d}K{d}L{d}L{d}K{d}K{d}L{d}L{d} | D-T25 | Free | Free | Branched | D | None | 38 | Antibacterial. Antibiofilm | MHC at 125 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 33242568 | 2021 | KKCNFFCKLKKKVKSVGSRNLIGSATHHHRIYRV | PN-CATH1 | Free | Free | Linear | L | None | 34 | Antibacterial, Antifungal, Antibiofilm, Anti-inflammatory, anitoxidant | 5.9 % Hemolysis at 200 μg/mL | Mouse | Black-Spotted Frog, Pelophylax Nigromaculata | SDS = α-Helical | Low hemolytic | ||
| 33890759 | 2021 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial | 50 % Hemolysis at 170 μM | Human | Human Cathelicidin Ll-37 | Helical | NA | ||
| 34301247 | 2021 | FKRIVQRIKRFLRGGGGSFKRIVQRIKRFLR | LG | Free | Free | Linear | L | None | 31 | Antibacterial | 20 % Hemolysis at 64 μM | Human | Synthetic Peptide | NA | NA | ||
| 34301247 | 2021 | FKRIVQRIKRFLRAEAAAKAFKRIVQRIKRFLR | LA | Free | Free | Linear | L | None | 33 | Antibacterial | 20 % Hemolysis at 32 μM | Human | Synthetic Peptide | NA | NA | ||
| 34058259 | 2021 | HAQQQAGSADASANNAKDDDVVDAEFEEVKDKK | DP7 | Free | Free | Linear | L | None | 33 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34282000 | 2021 | RLELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-inflammatory | >40 % Hemolysis at 80 μM | Human | Cathelicidin In Canines (Dogs) | 0.1% SDS or 50 μM LPS = α-Helical | NA | ||
| 34282000 | 2021 | ({nnr:Cit})LKELITTGGQKIGEKI({nnr:Cit})({nnr:Cit})IGQ({nnr:Cit})IKDFFKNLQP({nnr:Cit})EEKS | K9CATHCit5 | Free | Free | Linear | L | Cit = citrulline | 38 | Antibacterial | 0 % Hemolysis at 80 μM | Human | Cathelicidins Modified K9Cath | 0.1% SDS or 50 μM LPS = α-Helical | Non-hemolytic | ||
| 34282000 | 2021 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antibacterial | >25 % Hemolysis at 80 μM | Human | Human Cathelicidin Hcap18 | α-Helical | NA | ||
| 34282000 | 2021 | LLGDFF({nnr:Cit})KSKEKIGKEFK({nnr:Cit})IVQ({nnr:Cit})IKDFL({nnr:Cit})NLVP({nnr:Cit})TES | LL-37 Cit5 | Free | Free | Linear | L | Cit = citrulline | 37 | NA | 0 % Hemolysis at 80 μM | Human | Cathelicidins Modified Ll-37 | Helical | Non-hemolytic | ||
| 34576320 | 2021 | QAFQTFKPDWNKIRYDAMKMQTSLGQMKKRFNL | Ltc6a | Free | Free | Linear | L | None | 33 | Antibacterial | 3 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | Low hemolytic | ||
| 34576320 | 2021 | GETFDKLKEKLKTFYQKLVEKAEDLKGDLKAKLS | Ltc7 | Free | Free | Linear | L | None | 34 | Antibacterial | 2 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | Low hemolytic | ||
| 34708005 | 2021 | RVCFRPVAPYLGVGVSGAVRDQIGVKLGSVYKGPRG | Cc-AFP1 | Free | Free | Linear | L | None | 36 | Antifungal | 12.56 % Hemolysis at 128 μg/ml | Human | Carum Carvi (Caraway) | α-Helix and Random coil | Low hemolytic | ||
| 34302796 | 2021 | AGTKEWLNKAKDFIKEKGLGMLSAAANAALN | M-PONTX–Nc3b | Free | Free | Linear | L | None | 31 | Antimicrobial, anthelmintic, Insecticidal | 50 % Hemolysis at >300 μM | Human | Ant Neoponera Commutata | aqueous = Disordered, 20% TFE or 20 mM SOS = α-Helical | Low hemolytic | ||
| 34959645 | 2021 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antibacterial | 70 % Hemolysis at 200 μM | Human | Host Defense Peptide | PBS, 60mMSDS = Helical | NA | ||
| 34966279 | 2021 | RWRRPIRRRPIRPPFWRKGKGKGKRRVRWIIW{ct:Amid} | hyP7B5GK | Amidation | Free | Linear | L | None | 32 | Antibacterial | 50 % Hemolysis at >120 μM | Human | Hybrid Peptide With Gly-Lys Linker, Optp7 C-Terminal | NA | Low hemolytic | ||
| 34966279 | 2021 | RWRRPIRRRPIRPPFWRKGKC-S-S-CKGKRRVRWIIW{ct:Amid} | hyP7B5Cys | Amidation | Free | Linear | L | None | 35 | Antibacterial | 50 % Hemolysis at 102 μM | Human | Hybrid Peptide With Disulfide Bridge, Designed To Be Cleaved In The Cytosol, Optp7 C-Terminal | NA | NA | ||
| 36555393 | 2022 | VLTTGLPALISWIKRKRQQGGGGSK{d}L{d}A{d}K{d}L{d}A{d}K{d}K{d}L{d}A{d}K{d}L{d}A{d}K{d}{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | melittin-dKLA 8-26 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | Mix | None | 38 | Anticancer | <5 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | Non-hemolytic | ||
| 36903328 | 2023 | KRFKKFFKKLRKSVKKRVKKFFKKPKVIGVSIPF | Hydrostatin-AMP2 | Free | Free | Linear | L | None | 34 | Antibacterial, Antibiofilm | 4.6 % Hemolysis at 250 μg/mL | Human | Sea Snake Hydrophis Cyanocinctus | Water = Random coil, SDS = α-Helical | Low hemolytic | ||
| 37365421 | 2023 | RLCTNCCAGRKGCNYYSADGTFICEGESDPNNPKA | CaCPin-II | Free | Free | Linear | L | None | 35 | Antifungal, Anti‑Candida | 28 % Hemolysis at 200 μg/mL | Sheep | Sweet And Chili Pepper Plant Capsicum Annuum Leaves | Disordered, β-Sheet and α-Helix | Low hemolytic | ||
| 37365421 | 2023 | GQQSCLCGYMKQYVNSPNARKVVGQCGVSVPNC | CaCLTP2 | Free | Free | Linear | L | None | 33 | Antifungal, Anti‑Candida | 1.7 % Hemolysis at 200 μg/mL | Sheep | Sweet And Chili Pepper Plant Capsicum Annuum Leaves | Disordered, β-Sheet and α-Helix | Low hemolytic | ||
| 37513276 | 2023 | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV | Turgencin A | Free | Free | Linear | L | None | 36 | Antibacterial | 0 % Hemolysis at 10 μg/mL | Human | Fungi Pichia Pastoris | α-Helix and Random coil | Non-hemolytic | ||
| 37635252 | 2023 | GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSERFQS | PMAP-37(F34-R) | Free | Free | Linear | L | None | 37 | Antibacterial | ≤1.5 % Hemolysis at 0.36 μg/mL | Human | Pamp-37 (Pig Bone Marrow) Analogue | α-Helix | Low hemolytic | ||
| 35050481 | 2022 | TTLRLNTLAYKVAWLVNVKAFWAAGRALKKVGR | dendrocin-ZM1 | Free | Free | Linear | L | None | 34 | Antibacterial | >5 % Hemolysis at 16 μg/mL | Human | Zataria Multifora | α-Helix | Low hemolytic | ||
| 35050481 | 2022 | TTLRLNTLAYKVAWLVNVKAFWAAGRALKKVGR | dendrocin-ZM1 | Free | Free | Linear | L | None | 34 | Antibacterial | 17 % Hemolysis at 128 μg/mL | Human | Zataria Multifora | α-Helix | Low hemolytic | ||
| 35889198 | 2022 | GFGCNLITSNPYQCSNHCKSVGYRGGYCKLRTVCTCY | Actifensin | Free | Free | Linear | L | None | 37 | Antimicrobial | 1.25 % Hemolysis at 2895 µg/mL | Mouse | Actinomyces Ruminicola | NA | Low hemolytic | ||
| 35891269 | 2022 | KLFGKVGNLLQKGWQKIKNIGRRIKDFFRNIRPMQEA{ct:Amid} | To-KL37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | 16 % Hemolysis at 50 µM | Human | Cathelicidin-Derived | NA | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKCKISGGC | B2CE | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 56.92 µM | Human | Chinese Forest Frog Rana Chensinensis | α-Helix | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKCKISGGC | B2CE-nonDS | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 130.27 µM | Human | B2Ce Analogs | α-Helix | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKSKISGGS | B2CE-C31,37 S | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 25 µM | Human | B2Ce Analogs | α-Helix | NA | ||
| 35910608 | 2022 | GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG | PMAP-36 | Free | Free | Linear | L | None | 36 | Antimicrobial | <20 % Hemolysis | mouse | Synthetic | NA | Low hemolytic | ||
| 35966656 | 2022 | KWKLFKKIHKVGQNIRKGIIKAGPAVAVVGQAAQIAK | PEW300 | Free | Free | Linear | L | None | 37 | Antibacterial, Antibiofilm | 0 % Hemolysis at 50 to 250 μg/ml | Mouse | Synthetic | α-Helix | Non-hemolytic | ||
| 35812346 | 2022 | PRRRRSSSRPIRRRRPRRASRRRRRGGRRRR{nt:H}{ct:OH} | Protamine (sulfate) | OH | H | Linear | L | None | 31 | Mast cell degranulation inducer | No Hemolysis at 16 μM | Human | Synthetic | NA | Non-hemolytic | ||
| 36044031 | 2022 | GSVPCGESCVWIPCIS-GILGCSCSNKVCYYN{cyc:N-C} | anpy A | Free | Free | Cyclic | L | None | 32 | Cytotoxic | 50 % Hemolysis at 22 μM | Human | Anchietea Pyrifolia | NA | NA | ||
| 36044031 | 2022 | SIPCGESCVWIPCTVTALAGCSCKNKVCYKN{cyc:N-C} | anpy B | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at 78 μM | Human | Anchietea Pyrifolia | NA | Low hemolytic | ||
| 36044031 | 2022 | GIPCGESCVWIPCIS-SAIGCSCKNKVCYRN{cyc:N-C} | cy04 | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at >156 μM | Human | Anchietea Pyrifolia | NA | Non-hemolytic | ||
| 36044031 | 2022 | GIPCGESCVWIPCIS-AAIGCSCKNKVCYRN{cyc:N-C} | cy017 | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at >156 μM | Human | Anchietea Pyrifolia | NA | Non-hemolytic | ||
| 24412436 | 2014 | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIND | SJGAP (Skipjack tuna GAPDH-related AMP) | Free | Free | Linear | L | None | 32 | Antibacterial, Antifungal | 0 % Hemolysis at <100μg/mL | Human | Fish Skipjack Tuna Katsuwonus Pelamis | one Alphα-Helix Strand, two parallel Betα-Strands, and 2 Loop regions | Non-hemolytic | ||
| 9257708 | 1997 | GWLRKAAKSVGKFYYKHKYYIKAAWQIGKHAL | Styelin D | Free | Free | Linear | L | None | 32 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolysis at <10μg/mL | Human | Sea Squirt, Styela Clava | Helix | NA | ||
| 9257708 | 1997 | GWLRKAAKSVGKFYYKHKYYIKAAWQIGKHAL | Styelin D | Free | Free | Linear | L | None | 32 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolysis at 40μg/mL | Sheep | Sea Squirt, Styela Clava | Helix | NA | ||
| 14978112 | 2004 | RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | human RK-31 | Free | Free | Linear | L | None | 31 | Antibacterial, Antifungal, candidacidal, Hemolytic | 6 % Hemolysis at 100µM | Human | Human Protease Truncation; Human Sweat, Homo Sapiens | NA | Low hemolytic | ||
| 16207177 | 2006 | GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD{cyc:N-C} | Kalata B8 | Free | Free | Cyclic | L | None | 31 | Antiviral, Anti-HIV, Hemolytic | 0 % Hemolysis at 370µM | Human | Plant African Herb, Oldenlandia Affinis | Beta | Non-hemolytic | ||
| 10477123 | 1999 | ALWKTMLKKLGTMALHAGKAAFGAAADTISQ | Dermaseptin-DI3 (DD M) | Free | Free | Linear | L | None | 31 | Antibacterial, Hemolytic | Hemolytic at >33µM | Human | Brazilian Frog, Phyllomedusa Distincta, South America | NA | NA | ||
| 21295070 | 2011 | GIFSALAAGVKLLGNTLFKMAGKAGAEHLACKATNQC | Esculentin-2PRb | Free | Free | Linear | L | None | 37 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 35µM | Human | Frog North America, The Oregon Spotted Rana Pretiosa | NA | NA | ||
| 22074926 | 2012 | GGSVPCGESCVFIPCITSLAGCSCKNKVCYYD{cyc:N-C} | Parigidin-br1 | Free | Free | Cyclic | L | None | 32 | Insecticidal, Hemolytic | 28 % Hemolytic at 20µM | Human | Plant Palicourea Rigida (Rubiaceae) | Bridge | NA | ||
| 22074926 | 2012 | GGSVPCGESCVFIPCITSLAGCSCKNKVCYYD{cyc:N-C} | Parigidin-br1 | Free | Free | Cyclic | L | None | 32 | Insecticidal, Hemolytic | 41 % Hemolytic at 40µM | Human | Plant Palicourea Rigida (Rubiaceae) | Bridge | NA | ||
| 21303203 | 2011 | GLWDSIKNFGKTIALNVMDKIKCKIGGGCPP | Palustrin-2CE | Free | Free | Linear | L | None | 31 | Antibacterial, hemolytic | 50 % Hemolytic at 64µM | Human | The Chinese Brown Frog, Rana Chensinensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | SLFSIFKTAAKFVGKNLLKQAGKAGLETLACKAKNEC | Esculentin-2CG1 | Free | Free | Linear | L | None | 37 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 75µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | GLWNTIKEAGKKFAINVLDKIRCGIAGGCKT | Palustrin-2CG1 | Free | Free | Linear | L | None | 31 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 75µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | GILDKLKEFGISAARGVAQSLLNTTASCKLAKTC | Brevinin-2CG1 | Free | Free | Linear | L | None | 34 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 75µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 19633086 | 2009 | NKGCAICSIGAACLVDGPIPDFEIAGATGLFGLWG | Subtilosin A1 | Free | Free | Linear | L | None | 35 | Antibacterial Gram+, Hemolytic | Hemolytic at 16µM | Rabbit | Bacteria Mutant Produced In B. Subtilis | NA | NA | ||
| 25066917 | 2014 | SILSTLKDVGISAIKSAGSGVLSTLLCKLNKNC | Brevinin-2TP1 | Free | Free | Linear | L | None | 33 | Antibacterial, Hemolytic | 50 % Hemolytic at 18.2µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | GLWNTIKEAGKKFALNLLDKIRCGIAGGCKG | Palustrin-2GN1 | Free | Free | Linear | L | None | 31 | Antibacterial, Antioxidant, Hemolytic | 50 % Hemolytic at 46.4µM | Human | Frog Skin Secretions, Amolops Granulosus, China, Asia | NA | NA | ||
| 31328553 | 2021 | SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC{ct:Amid} | Esculentin-2 HYba1 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 15µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC{ct:Amid} | Esculentin-2 HYba2 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 12µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC | Esculentin-2 HYba1 | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 10µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC | Esculentin-2 HYba2 | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 10µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 37938588 | 2023 | MSTRSSSIRRLVEAVRTRFRAALRTVLFFALRTTKRRPRR | CFPS_AMP_23 | Free | Free | Linear | L | None | 40 | Antibacterial, Hemolytic | 50 % Hemolytic at 11.5µM | Human | Synthetic Peptide | NA | NA | ||
| 22917879 | 2012 | GLLDTFKNLALNAAKSAGVSVLNSLSCKLSKTC{ct:OH} | Brevinin-2JD | OH | Free | Linear | L | None | 33 | Antimicrobial | 11.7 ± 3.2 % Hemolytic at 128µg/ml | Rabbit | Odorrana Jingdongensis (Jingdong Frog) (Rana Jingdongensis) | α-Helical | Low hemolytic | ||
| 30214940 | 2018 | GLGRLIGKIAKKGAKIAAEAAANAAAEKAAEAL{ct:Amid} | U-myrmeciitoxin(01)-Mg1a (MIITX(01)-Mg1a) (U-MIITX(01)-Mg1a) | Amidation | Free | Linear | L | None | 33 | Antimicrobial | HC(50) % Hemolytic at >10.2µM | Human | Myrmecia Gulosa (Red Bulldog Ant) | NA | Non-hemolytic | ||
| 19101583 | 2008 | ADDKNPLEECFRETDYEEFLEIARNGLKATSNPKRVV | L-amino-acid oxidase (BjarLAAO-I) (LAO) (EC 1.4.3.2) | Free | Free | Linear | L | None | 37 | Antimicrobial | Hemolytic | Horse | Bothrops Jararaca (Jararaca) (Bothrops Jajaraca) | NA | NA | ||
| 17046111 | 2006 | MSAEALADPKADPLAGPNPDADPEAINLKAIAALAKKLLG{ct:Amid} | Mastoparan-like peptide 12c | Amidation | Free | Linear | L | None | 40 | Antimicrobial | Low hemolytic | Human | Vespa Magnifica (Hornet) | NA | Low hemolytic | ||
| 19944711 | 2010 | AHDGNPLEECFREDDEEFFLEIAKNGLTATSNPKRVVIV{ct:Amid} | L-amino-acid oxidase (BmarLAAO) (LAO) (EC 1.4.3.2) | Amidation | Free | Linear | L | None | 39 | Antibacterial and Antiparasitic | Hemolytic | NA | Bothrops Marajoensis (Marajo Lancehead) | NA | NA | ||
| 19253295 | 2008 | YDLSKNCRLRGGICYIGKCPRRFFRSGSCSRGNVCCLRFG | Beta-defensin 1 (TBD-1) | Free | Free | Linear | L | None | 40 | Antimicrobial | 0 % Hemolytic at 25µmol/L | Human | Emys Orbicularis (European Pond Turtle) | NA | Non-hemolytic | ||
| 15197474 | 2004 | ACQFWSCNSSCISRGYRQGYCWGIQYKYCQCQ | Defensin-1 (Cll-dlp) | Free | Free | Linear | L | None | 32 | Antimicrobial | Hemolytic | Human | Centruroides Limpidus (Mexican Scorpion) | NA | NA | ||
| 22438972 | 2012 | IKFEPPLPPKKAHKKFWEDDGIYYPPNHNFP | L-amino-acid oxidase (Bm-LAO) (LAAO) (EC 1.4.3.2) | Free | Free | Linear | L | None | 31 | Antibacterial Antiparasitic | 12.5+-5.3 % Hemolytic at 512μg/mL | Human | Bothrops Mattogrossensis (Pitviper) (Bothrops Neuwiedi Mattogrossensis) | NA | NA | ||
| 22450466 | 2012 | SLLGTVKDLLIGAGKSAAQSVLKGLSCKLSKDC | Brevinin-2HS2 | Free | Free | Linear | L | None | 33 | Antibacterial, Antifungal | 50 % Hemolytic at 300µM | Human | Odorrana Hainanensis (Odor Frog) (Rana Hainanensis) | Helical | Low hemolytic | ||
| 11682065 | 2001 | GLLDSIKGMAISAGKGALQNLLKVASCKLDKTC | Nigrocin-1 | Free | Free | Linear | L | None | 33 | Antibacterial, Antifungal | 1.1 % Hemolytic at 100μg/mL | Human | Pelophylax Nigromaculatus (Black-Spotted Frog) (Rana Nigromaculata) | α-Helical | Non-hemolytic | ||
| 9784389 | 1998 | GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP | Ranatuerin-2 | Free | Free | Linear | L | None | 31 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | GFLDIINKLGKTFAGHMLDKIKCTIGTCPPSP | Ranatuerin-3 | Free | Free | Linear | L | None | 32 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic |